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TERMS AND ABBREVIATIONS 
 
Abbreviation Full term 
lncRNAs Long non-coding RNAs 
PC  Protein-coding 
BCP-ALL B-cell precursor Acute lymphoblastic leukemia 
DUX4 Double homeobox 4 
Ph-like Philadelphia-like (Ph-like) 
NH-HeH Near haploid/High hyper-diploid 
BM Bone Marrow 
ID Initial diagnosis 
REL Relapse 
HSCs Hematopoietic stem cells 
AML Acute Myleoid Leukemia 
JAK-SAT Janus kinase and Signal Transducer and Activator of 
Transcription 
mTOR mammalian Target of Rapamycin 
PI3K-Akt Phosphatidylinositol 3'-kinase 
TGF-β Transforming Growth Factor 
RNA-Seq  RNA sequencing 
CAMs Cell adhesion molecules 
FPKM Fragments Per Kilobase Million 
PVT1 Plasmacytoma variant translocation 1 
LUCAT1 Lung Cancer Associated Transcript 1 
TCL6 T-cell leukemia/lymphoma 6 
HOTAIRM1 HOX antisense intergenic RNA myeloid 1 
ANRIL Antisense Non-coding RNA in the INK4 Locus 
TERRA Telomeric repeat-containing RNA 
MIAT Myocardial infarction associated transcript 
CRNDE Colorectal neoplasia differentially expressed 
GAS5 Growth arrest-specific 5 




HOTTIP HOXA transcript at the distal tip 
DLEU1 Deleted Lymphocytic Leukemia 1 
IKZF1  Ikaros family zinc finger protein 1 
SAMD-AS2 SMAD family member one antisense 2 
SMAD SMAD family member 1 
ITGA6 Integrin alpha-6 
CDK6 Cyclin-dependent kinase 
IL2RA Interleukin-2 receptor alpha chain 
STAR Spliced Transcripts Alignment to a Reference 
LIMMA Linear Models for Microarray Data 
GREAT Genomic Regions Enrichment of Annotations Tool 
SWAN Subset-quantile within array Normalization 
TSS Transcription start site 
DE Differential expression 
DM Differential Methylated 
GTF Gene transfer format 
BED Browser Extensible Data 
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Einführung: Die B-Vorläufer akute lymphatischen Leukämie (BCP-ALL) ist eine heterogene 
Krebserkrankung mit mehreren definierten Subgruppen. Neue Daten deuten darauf hin, dass lange nicht-
kodierende RNAs (long noncoding RNAs - lncRNAs) eine Schlüsselrolle bei der Entwicklung und 
Progression der BCP-ALL spielen könnten.  Daher führten wir eine Transkriptions- und DNA-
Methylierungsstudie durch, um die lncRNA-Landschaft von drei BCP-ALL-Subgruppen (82 Proben) zu 
charakterisieren und potentielle regulative Konsequenzen zu analysieren. 
 
Methodik: Material wurde zum Zeitpunkt der Erstdiagnose (ID) und im Rezidiv (REL) von erwachenen 
(n = 21) und pädiatrischen (n = 24) BCP-ALL-Patienten entnommen und unter Verwendung von RNA-
Seq und DNA-Methylierungs-Array-Technologien untersucht. Die Subgruppen-spezifischen und 
rezidiv-spezifischen lncRNAs wurden durch differentielle Expressions (DE) Analysen mit LIMMA 
Voom analysiert. Durch die Analyse der Koexpression von lncRNAs mit Protein-kodierenden (PC) 
Genen aus allen Subgruppen schlossen wir unter Verwendung eines ‚Guilt-by-association‘ -Ansatzes auf 
potentielle Funktionen der DE lncRNAs. Zudem haben wir die Subgruppen-spezifischen lncRNAs auf 
einem unabhängigen Datenset von 47 BCP-ALL-Proben validiert. Die epigenetische. Die epigenetische 
Regulation von Subgruppen-spezifischen lncRNAs wurde durch eine differentielle Methylierungs (DM) 
analyse identifiziert. Die Korrelation zwischen DM und DE lncRNAs aus drei Subgruppen wurde 
ermittelt, um den Einfluss der epigenetischen Regulation auf die Expression von lncRNAs zu 
analysieren. 
Ergebnisse: Wir präsentieren eine umfassende Landschaft von lncRNA-Signaturen, die drei molekulare 
Subtypen von BCP-ALL auf DNA-Methylierungs- und RNA-Expressionslevel klassifiziert. Die 
Hauptkomponentenanalyse (PCA) auf den top variablen lncRNAs auf RNA und DNA-
Methylierungsniveau bestätigte eine robuste Trennung von Ph-like, DUX4 und NH-NeH BCP-ALL 
Subtypen. Mit integrativer bioinformatischer Analyse, zusammen 1564 subtyp-spezifische und 941 
rezidiv-spezifische lncRNAs aus den drei Subtypen. Das unüberwachte hierarchische Clustering auf 
diesen Subtyp-spezifischen lncRNAs validierte ihre Spezifität in der unabhängigen Validierungskohorte. 
Unsere Studie zeigt erstmals, dass BCP-ALL-Subtyp-spezifische sowie Rezidiv-spezifische lncRNAs 
zur Aktivierung von Signalwegen wie TGF-β, PI3K-Akt, mTOR und Aktivierung von JAK-STAT-
Signalwegen von DUX4 und Ph-like Subtypen. Endlich wurden die signifikant DM subtyp-spezifische 




und Hypermethylierungsmuster in ihrer Promotorregion zeigen, das signifikant mit ihrer verringerten 
und erhöhten Expression in den jeweiligen Subtypen korreliert. 
Schlussfolgerungen: Insgesamt liefert unsere Arbeit die umfassendsten Analysen für lncRNAs in BCP-
ALL-Subtypen. Unsere Ergebnisse weisen auf eine Vielzahl von biologischen Funktionen im 
Zusammenhang mit lncRNAs und epigenetisch erleichterten lncRNAs in BCP-ALL hin und bieten eine 








Introduction: B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is the most prevalent 
heterogeneous cancer in children and adults, with multiple subtypes. Emerging evidence suggests that 
long non-coding RNAs (lncRNAs) might play a key role in the development and progression of 
leukemia. Thus, we performed a transcriptional and DNA methylation survey to explore the lncRNA 
landscape on three BCP-ALL subtypes (82 samples) and demonstrated their functions and epigenetic 
profile. 
Methodology: The primary BCP-ALL samples from bone marrow material were collected from 
diagnosis (ID) and relapse (REL) stages of adult (n = 21) and pediatric (n = 24) BCP-ALL patients, using 
RNA-seq and DNA methylation array technology. The subtype-specific and relapse-specific lncRNAs 
were analyzed by differential expression (DE) analysis method using LIMMA Voom. By analyzing the 
co-expression of the subtype-specific lncRNAs and protein-coding (PC) genes from all subtypes, we 
inferred potential functions of these lncRNAs by applying “guilt-by-association” approach. Additionally, 
we validated our subtype-specific lncRNAs on an independent cohort of 47 BCP-ALL samples. The 
epigenetic regulation of subtype-specific lncRNAs were identified using the Bumphunter package. The 
correlation analysis was performed between DM and DE lncRNAs from three subtypes to determine the 
epigenetically facilitated and silenced lncRNAs. 
Results: We present a comprehensive landscape of lncRNAs signatures which classifies three molecular 
subtypes of BCP-ALL on DNA methylation and RNA expression levels. The principle component 
analysis (PCA) on most variable lncRNAs on RNA and DNA methylation level confirmed robust 
separation of DUX4, Ph-like and NH-HeH BCP-ALL subtypes. Using integrative bioinformatics 
analysis, subtype-specific and relapse-specific lncRNAs signature together determine 1564 subtype-
specific and 941 relapse-specific lncRNAs from three subtypes. The unsupervised hierarchical clustering 
on these subtype-specific lncRNAs validated their specificity on the independent validation cohort. For 
the first time, our study demonstrates that BCP-ALL subtype specific as well as relapse-specific lncRNAs 
may contribute to the activation of key pathways including TGF-β, PI3K-Akt, mTOR and activation of 
JAK-STAT signaling pathways from DUX4 and Ph-like subtypes. Finally, the significantly hyper-
methylated and hypo-methylated subtype-specific lncRNAs were profiled. In addition to that, we 
identified 23 subtypes specific lncRNAs showing hypo and hyper-methylation pattern in their promoter 





Conclusions: Overall, our work provides the most comprehensive analyses for lncRNAs in BCP-ALL 
subtypes. Our findings suggest a wide range of biological functions associated with lncRNAs and 
epigenetically facilitated lncRNAs in BCP-ALL and provide a foundation for functional investigations 






Chapter 1. Introduction 
1.1  History of long non-coding RNAs (lncRNAs) 
The flow of genetic information through and by messenger Ribonucleic acid (mRNA) came into light 
through the paper “Genetic Regulatory Mechanisms in the Synthesis of Proteins,” in 1961 (Jacob & 
Monod, 1961). Since then, a myriad of studies discovered a large variety of RNA of different size and 
shape (Figure 1.2.1). Jacob & Monod postulated in their paper that lncRNAs resemble mRNA, yet they 
do not encode protein. Instead, lncRNAs facilitate a wide variety of mechanisms which regulate the 
production of gene products such as other RNAs or proteins. Today, lncRNAs have emerged as a critical 
layer in the genetic regulatory code. Proceeding studies and biochemical experiments were able to 
characterize the abundant structure and regulatory RNAs by locating their cellular localization and 
sequence similarity. Genetic studies identified a few lncRNAs involved in genomic imprinting and other 
cellular processes. For example, XIST, H19 and AIR (Rinn & Chang, 2012). Collectively, all these 
classical studies identified a diverse range of RNA, but they only superficially looked on the cell surface 
for functions of all those identified RNAs. 
1.2  Definition of lncRNAs 
The new century has started with the completion of the Human genome project and discovered numerous 
new RNA encoding genes but no new protein-coding genes, which revealed a biological mystery about 
human genome: The human genome comprises only about 2% of protein-coding genes, and the rest is 
non-coding RNAs. The non-coding RNAs are subdivided into two types, small non-coding RNAs and 
long non-coding RNAs (lncRNAs). The small non-coding RNAs are microRNAs and other RNAs. The 
lncRNAs were defined as RNA genes >= 200 base pair (bp) in length and either no or short open reading 
frame (ORF). The definition is somewhat arbitrary because some small regulatory RNAs are higher than 
200 nucleotides in length. Although this definition is arbitrary, the threshold separates lncRNAs from 
other small regulatory non-coding RNAs such as microRNAs (miRNAs) or Piwi-associated small RNAs 




The advent of full genome sequencing enabled prospecting for new “genes”, which surprisingly led to 
the discovery of more RNAs than protein-coding genes. For instance, the number of human microRNAs 
(miRNAs) quickly increased from a few to nearly thousands. Transcriptome analysis by arrays and RNA 
sequencing (RNA-Seq) studies have demonstrated that a significant portion of the transcriptome consists 
of lncRNAs. However, by the discovery of next-generation technologies the scenario has been changed, 
and now lncRNAs are being studied widely on both molecular and genetic level because of their 
significant functions in a variety of disease and normal tissues/cells. 
 
1.3  Genomic features and classification of lncRNAs 
Most, but not all lncRNAs are transcribed by RNA polymerase II and are capped and polyadenylated at 
their 5′ and 3′ ends respectively (Rinn & Chang, 2012). LncRNAs are often defined by their location in 
the genome. Most of them are found near protein-coding (PC) genes, e.g. within exons of PC genes, 
introns of genes, and in intergenic regions. The classification of lncRNAs based on their anatomy in the 
genome. The biotypes of lncRNAs are, antisense, the lncRNAs that overlap PC genes in the opposite 
strand, sense intronic lncRNAs that are encoded within introns of PC genes, and sense overlapping 
lncRNAs are termed based on their transcripts overlapping PC genes. The lncRNAs located between PC 
genes are named long intergenic non-coding RNAs (lincRNAs) (Figure 1.3.1) (Atianand & Fitzgerald, 
2014). Most of the lncRNAs have multiple exons and are subjected to alternative splicing, but they have 
fewer exons than PC genes. 
 
Figure 1.2.1: The time flow of the lncRNAs discovery. 
The figure represents the discovery flow of lncRNAs from the time when nucleic acid was discovered until 2011. 





1.4  Identification of lncRNAs 
Currently, there are no standard criteria for identification of lncRNAs and most researchers use arbitrary 
thresholds to define lncRNAs. A widely accepted definition is based on the ORF size and was defined 
by the FANTOM (Functional Annotation of Mouse) project where they defined a threshold of 100 
codons, to separate lncRNAs from other mRNAs genes (Kawai et al., 2001). However, the classification 
criteria of lncRNAs are straightforward and practical; they are subject to false positives and false 
negatives. For example, the XIST lncRNA in the murine cell line is approximately 15kb in size and 
contains 298 amino acids in ORF, which were mistaken for the protein-coding genes (Borsani et al., 
1991). Various approaches can be applied to rationalize this problem. 
The task of defining and annotating or separating lncRNAs from mRNAs is complex and suffers from 
the lack of specific defining criteria. The methods including machine learning approach and sequence 
conservation methods sonly provides an estimate of the likelihood that an RNA sequence is coding or 
non-coding. Such a dichotomous classification into mRNAs and lncRNAs might have little biological 
relevance as there isn’t necessarily a clear distinction between the two classes. In a real-world point of 
view, the fact that RNAs with an exclusive coding or non-coding function are only the two extremes of 
a continuous process. Therefore, a definitive answer for coding and non-coding potential can only be 
observed by investigating the proteome experimentally in the wet lab. 
 
Figure 1.3.1: The classification of lncRNAs. 
The anatomical definition of long non-coding RNAs (lncRNAs), based on their location within transcriptome. The 
diagram represents, lincRNA, intronic, Antisense and sense overlapping lncRNAs. This diagram is adapted from 




1.5  Technologies used in the identification of lncRNAs 
Identification of lncRNAs are based on all the transcripts obtained from the cell including coding, non-
coding, and mRNAs isoforms. Advanced microarray technologies and RNA-Seq can be used for 
identifying lncRNAs within the cell. RNA-Seq, in contrast, is not only limited to the identification of 
known lncRNAs but also novel unannotated lncRNAs. 
1.5.1  Microarray technologies in lncRNA identification 
Conventional microarray technologies use predestined probes to find the expression level of mRNA 
transcripts and are not able to identify new lncRNAs. Nevertheless, it has been found that a few 
previously defined probe sequences are lncRNAs; therefore, microarray data analysis requires re-
annotation of the probes in order to study the expression of lncRNAs. New specific probes for lncRNAs 
can be designed with the discovery of new and more lncRNAs. For example, some study groups designed 
probes matching conserved regions (intergenic and intergenic region) to identify potential non-coding 
RNA (nc-RNA) transcripts (Babak, Blencowe, & Hughes, 2005). However, micro-arrays are limited due 
to the low expression level of many lncRNAs. 
1.5.2  RNA-Seq in identification of lncRNAs 
The arrival of the deep sequencing technology led to the ability to sequence cDNA (derived from RNA), 
using the technology called RNA-seq, a high throughput and dynamic sequencing method with the 
unparalleled scale of data production. These approaches have been coupled to computational methods 
allowing the reconstruction of transcripts and their isoforms at single nucleotide resolution (Trapnell, 
Pachter, & Salzberg, 2009). The studies have provided an unbiased identification of non-coding 
transcripts across many cell types and tissues (Guttman et al., 2010). RNA-seq is widely used for 
discovery of novel transcripts and gene expression analysis. Advancement of RNA-seq, allowed 
consortia to define all the transcribed genes in the genome and to release broad catalogs. For instance, 
the GENCODE project released one of the complete evidence-based human reference genomes based on 
RNA-seq analysis on multiple cell types. The catalog consists of more than 15787 lncRNAs in the latest 
version (GRCh38) (Mudge & Harrow, 2015). 
RNA-Seq has many advantages in studying gene expression, compared to microarray. RNA-seq more 
sensitive in detecting less-abundant transcripts, identifying novel alternative splicing isoforms and novel 
nc-RNA transcripts. Alternative splicing (AS) is a process by which exons or portions of exons or non-
coding regions within a pre-mRNA transcript are differentially excluded or included, resulting in multiple 




depth of sequencing and read lengths has allowed some of the first steps towards characterizing lncRNAs 
on a global scale. RNA sequencing has been utilized to estimate transcript abundance and to identify 
specific properties of distinct classes of large RNA genes in order to catalog them in a functional atlas by 
incorporating novel lncRNAs (Iyer et al., 2015). For example, a recent study identified 8,000 large 
intergenic non-coding RNAs (lincRNAs) in the human genome by integrating numerous annotation 
sources in combination with RNA sequencing (Arrial, Togawa, & Marcelo, 2009). This study revealed 
several global properties of lncRNAs, including investigating tissue-specific expression patterns, 
determining thousands of orthologous lincRNAs between human and mouse, and locating lncRNAs in 
gene deserts (the regions in the genome without any protein-coding genes) associated with the genetic 
trait. RNA-seq is now the gold standard method to discover lncRNAs, but a significant challenge with 
these data is their interpretation. Sequence reads commonly harbor multi-mapping potential, especially 
for lncRNAs whose DNA sequence is overall less conserved and harbors a higher degree of repetitive 
elements. Thus, stringent filtration and rigorous analysis are required to eliminate spurious transcripts. 
Other methods to identify lncRNAs and characterize their function, are: RNA immunoprecipitation (RIP) 
sequencing, RIP-Seq is a protein centric approach used to find the association of specific protein with 
RNAs or non-coding RNAs, which uses a protein as bait to pull-down RNAs. However, the RIP-Seq 
approach has its limitations, for example, the task of differentiating the direct or indirect interactions 
between protein and RNA is difficult. In addition to that, the read length of associated RNAs are too large 
for identifying the actual binding sites. Finally, the assays used for RIP-Seq technology are known for 
having variability. Thus, multiple biological replicates are necessary. 
1.6  Functions of lncRNAs 
In contrast to the significant progress made in identifying and classifying lncRNAs, the functional role 
and mechanisms of lncRNAs remained mostly unknown. However, during the last decade, researchers 
investigating the role and functions of lncRNAs have exceedingly increased and made clear that 
lncRNAs have a broad spectrum of specific functional features in various biological processes. By now 
it is clear that some of these lncRNAs participate in various biological processes such as regulation of 
gene expression both in cis and trans, genome imprinting, X-inactivation, development, differentiation, 
and cell cycle regulation (Kitagawa, Kitagawa, Kotake, Niida, & Ohhata, 2013). 
As of 2016, a literature-based lncRNAs database called lncRNAdb has shown 294 functionally annotated 
lncRNAs (Amaral, Clark, Gascoigne, Dinger, & Mattick, 2011). Below, I summaries the different types 




1.6.1  LncRNAs regulates the expression of their cis genes 
LncRNAs exert their functions mainly in combination with co-expressing with their nearby (cis) and 
distant (trans) protein-coding genes (Guil & Esteller, 2012) (Ali et al., 2018). LncRNAs interact with 
genes in the same genomic loci are termed as cis-lncRNAs, while trans acting lncRNAs interact with 
genes on same or on different chromosomes. Recently, there were several reports of lncRNAs co-
expression with its nearby protein-coding genes in several diseases and differentiation stages (Delás & 
Hannon, 2017). The cis-regulatory lncRNAs are mainly transcribed from the same promoters and 
enhancers of protein-coding genes, as well as from the antisense transcripts. Among these, antisense 
lncRNAs are epitomized due to their transcription regulatory activity at the cis region. Reports from 
FANTOM consortium suggested about 20% of transcribed PC gene has antisense lncRNAs (Kiyosawa 
et al., 2003). The antisense lncRNAs exert their function on their corresponding sense PC by influencing 
their genes expression at different levels, including transcriptional interference, and translation 
regulation. The following are a few examples of cis-regulatory lncRNAs. 
Transcriptional interference: Transcriptional interference is mainly through epigenetic interaction, and 
through impacting PC genes. One of the best-studied examples is the antisense lncRNA ANRIL, which 
contributes to cancer initiation by reducing senescence through protein interaction contributing to the 
repression of tumor suppressor genes. For example, ANRIL is encoded by CDKN2B-AS1 which is 
expressed at the CDKN2B-CDKN2A gene-cluster locus. The CDKN2B-CDKN2A gene-cluster locus 
encodes three major tumor suppressor genes, P14, P15 and P16, whose expression is subject to Polycomb 
group protein control. The antisense ANRIL has been shown to interact with the CBX7 protein, which is 
a component of the polycomb receptor factor 1 (PRC1), which can recognize H3K27me3 repressive 
marks on the genome. The CBX7 protein uses different regions within its domain for binding to 
H3K27me3 and antisense ANRIL; reports suggest that both interactions are important for sustained 
repression of the CDKN2B-CDKN2A gene-cluster locus (Qiu et al., 2016). 
Translational regulation: Antisense lncRNAs exert their functions as a translational control over the 
sense region of PC genes. For example, the antisense lncRNA BACE1-AS, increases the stability of its 
sense PC gene BACE1 through the formation of RNA duplex in the ~100-nt region. Antisense lncRNA 
BACE1-AS acts as a positive regulator of BACE1 protein by preventing the mi RNA-induced silencing. 
BACE1 is a protein being present at higher levels in brains of Alzheimer's patients (Faghihi et al., 2008). 
On the other hand, the trans-acting lncRNAs may act as signals, guides or scaffolds to chromatin to 
regulate the expression of target genes located in the distant chromosomal domains or even at different 




1.6.2  Transcriptional regulatory functions of lncRNAs in trans region 
The actual transcriptional regulatory functions of lncRNAs remain mostly unknown. Currently, based on 
the evidence and functionally characterized lncRNAs, the transcriptional regulation of lncRNAs serve 
mainly as a signal, decoy, guide, scaffold, and enhancer during the transcriptional process (Ma et al., 
2012). 
Signal: The transcription of individual lncRNAs occurs at a particular time and place to incorporate 
developmental evidence, interpret cellular context, or respond to diverse stimuli. Thus, the lncRNAs can 
serve as molecular signals at the transcription process (Figure 1.6.1 A). 
Decoy: The lncRNAs are capable of acting as decoys to DNA-binding proteins such as transcription 
factors, chromatin modifying proteins or enhancers (Groen, Capraro, & Morris, 2014). The mode of 
action is mainly through the sequence homology to the target gene, such as these lncRNAs can prevent 
and bind their interaction with target genes by acting as bait to their specific effector proteins (Figure 
1.6.1 B). 
Guide: These lncRNAs guide the localization of ribonucleoproteins to specific target sites (Figure 1.6.1 
C). 
Scaffold: LncRNAs act as a scaffold by interacting with multiple components and activate or repress 
transcription. LncRNAs can bind with two or more protein partners, in which lncRNAs serve as a device 
to form functional protein complexes (Figure 1.6.1 D). 
Enhancer: Using chromatin immunoprecipitation coupled with deep sequencing (ChIP-seq), it has 
shown that gene-activating enhancers give rise to lncRNA transcripts, known as enhancer RNAs (Visel 
et al., 2009). In addition to that, their expression level positively correlates with that of nearby PC genes, 
predicting that lncRNAs are more likely to regulate mRNA synthesis. Along the same line, another Loss-
of-Function study found that of 7 out of 12 lncRNA knockdowns affects the expression of their 
neighboring primal genes (Ørom et al., 2010). The lncRNAs also function as an activator of nearby genes 
via their “enhancer” function. These lncRNAs are from other genomic regions than enhancers which are 





1.7  Epigenetic gene regulation 
The most studied lncRNAs expression regulation is on the epigenetic level (C. Wang et al., 2017). 
Epigenetic modification is heritable changes in genome leading to change in gene function without 
changing DNA sequences. As RNA is an integral component of chromatin, many regulatory lncRNAs 
can function by interacting with chromatin modifiers and re-modelers to change the epigenetic status of 
the target gene. Chromatin modification is one of the epigenetic processes, in which the chromatin 
architecture is modified. The modification is to allow access of condensed genomic DNA to the 
regulatory transcription machinery proteins, and thereby control gene expression. Rising information 
 
Figure 1.6.1: Molecular functions of lncRNAs 
A. Signal: The figure shows the lncRNA KCNQ1OT1 which induces transcriptional silencing by recruiting histone-
lysine N-methyltransferase (EHMT2) and polycomb repressive complex 2 (PRC2) to a specific active site through 
chromatin methylation. B. Decoy: In the figure, alternative splicing is regulated by the lncRNA MALAT1 by trapping 
the serine and arginine amino acid residues (SR, proteins involved in RNA splicing). C. Guide: FENDRR either 
silences or activate gene expression by forming a complex with PRC2 and with TrxG/All proteins respectively. D. 
Scaffold: Chromatin methylation is modulated by CDKN2B-AS1 (also known as ANRIL) by binding to PRC1 and 
PRC2. E. Enhancer lncRNAs acts through chromosomal looping by an interaction between enhancer and promoter 
regions of genes, and it modulates target gene expression. Abbreviations: HxKy, histone (number x) lysine (number 




convey that some lncRNAs ‘guide’ chromatin-modifying complexes (Khalil et al., 2009) as well as other 
nuclear proteins to specific genomic loci to utilize their effects (P. Han & Chang, 2015). Critical 
epigenetic regulations of lncRNAs are highlighted in the following session. 
1.7.1  LncRNAs involved in chromatin-modifications 
Many lncRNAs were initially characterized based on their repressive functions, including ANRIL, 
HOTAIR, H19, KCNQ1OT1, and XIST (Bhat et al., 2016). The repressive function of these lncRNAs is 
achieved by coupling with histone modifying or chromatin re-modeling protein complexes. The most 
common chromatin modifying complexes coupled with these lncRNAs are the polycomb repressive 
complexes 1 and 2 (PRC1 and PRC2). These complexes facilitate the chromatin compaction and 
heterochromatin formation in order to enact repression of gene transcription by transferring repressive 
post-translational modifications to specific amino acid positions on histone tail proteins. (Leeb et al., 
2010). 
Nearly 20% of lncRNAs are estimated to bind with PRC2 (Khalil et al., 2009). However, the biological 
meaning of this observation is not yet clear, it is possible for PRC2 to bind promiscuously with lncRNAs 
in a non-specific way. Nevertheless, if lncRNAs are predominantly functioning in the cis-regulatory 
mechanism, then the PRC2 binding is to facilitate local gene expression through the genome. Examples 
of these category lncRNAs include ANRIL and XIST. Likewise, PRC1 proteins, especially 
heterochromatin protein 1 (or CBX) proteins, have been involved in ncRNA-based biology. 
1.7.2  LncRNAs in genomic imprinting and X chromosome inactivation 
Genomic imprinting is an epigenetic phenomenon where epigenetic marks at specific loci are set, based 
on the sex of the parent of origin of the chromosome, and usually leads to expression of genes from only 
one chromosome. The transcription and post-transcription-based gene regulation by lncRNAs can be 
studied using genomic imprinting. In addition to that, reports suggest that imprinted lncRNAs may fine-
tune gene expression of protein-coding genes to maintain their dosage in the cell (Kanduri, 2015). The 
XIST lncRNA is one of the classical examples in chromatin modifying lncRNAs. The lncRNA XIST 
mediates the chromatin regulation leading to the X chromosome dosage compensation in mammals. 
Briefly, dosage compensation refers to the process of equalizing the gene expression level of two X 
chromosome in the female cell to the single X in male cells (Brockdorff & Turner, 2015). 
1.8  DNA Methylation and lncRNAs 




functions, such as repression of gene transcription, maintaining genomic integrity, establishing, and 
repression of transposable elements (Moore, Le, & Fan, 2013). DNA methylation involves the addition 
of methyl group to cytosines. The genome contains CpG-rich regions, known as CpG island, which is 
often located at the promoter and first-exon regions. Usually, these regions are un-methylated, but when 
they are methylated, it blocks the transcription of related genes. LncRNAs have recently discovered as 
novel regulators of gene expression at the epigenetic level (Y. Zhao, Sun, & Wang, 2016). There are 
emerging evidence establishing the interplay between lncRNAs and DNA methylation (Y. Zhao et al., 
2016). Recent studies have demonstrated several similarities in the methylation dynamics between 
protein-coding genes and lncRNAs, including, the TSS methylation distribution, relationship between 
promoter and gene expression (Li et al., 2017). One of the critical steps in epigenetic regulation during 
standard development programs is the establishment and maintenance of methylation patterns resulting 
in modulation of gene expression. Such processes are facilitated by several DNA methyltransferases 
(DNMTs). A recent publication from Chalei and colleagues reports one such example lncRNA which 
they demonstrated the lncRNA termed as Dali. The lncRNA Dali is expressed in the central nervous 
system. This lncRNA is essential for neural differentiation and to regulate neural gene expression 
partially through interacting with DNMT1 (Chalei et al., 2014). This interaction then affects DNA 
methylation at distal target promoters. 
In addition to the functions mentioned above, another molecular mechanism of lncRNAs are, they are 
highly tissued specific compared to PC genes (K. C. Wang & Chang, 2011). Recently, research groups 
have been studying the expression of lncRNAs in the global remodeling of the epigenome and during 
reprogramming of somatic cells to induced pluripotent stem cells (iPSCs). The study revealed certain 
lncRNAs have high cell specificity regarding gene expression (Huo & Zambidis, 2013). Another study 
on loss-of-function of most lincRNAs expressed in mouse embryonic stem (ES) cells showed that the 
knockdown of lincRNAs has a major outcome on gene expression patterns, which are equal to the effects 
of knockdown of known ES cell regulators (Guttman et al., 2011). These studies prefigured that lncRNAs 
might play significant roles in regulating the developmental process. Off late, the ENCODE project 
analysed 31 cell types for finding the tissue specificity of lncRNAs, and they found that many lncRNAs 
have specific expression pattern in brain cells (Quan, Zheng, & Qing, 2017). The emerging lines of 
evidence suggest that any dysregulation of these lncRNAs expression can be linked to a variety of human 
diseases from neuron diseases to cancer or tumours (Tang et al., 2013). All these studies indicate the 




Though considerable research development has been made since the discovery of lncRNAs, the challenge 
to elucidate the functions of lncRNAs remains. Unlike PC genes whose mutation would bring a drastic 
change in the phenotype, mutations in lncRNAs often do not cause a significant phenotype (Mattick, 
2009). Also, another cause to it is that lncRNAs are more likely to function at a specific condition or 
specific developmental process, and so condition-specific studies of lncRNAs are necessary. With the 
massive amount of omics data, described lncRNAs are accumulating, and therefore for their functional 
predictions, computational approaches have been used to design the experimental studies and brisken the 
understanding of lncRNAs. 
1.9  LncRNAs in cancer 
Cancer is one of the leading causes of death around the world, which is about for 8.8 million (World 
health organization, WHO) in 2015. Understanding the underlying causes of cancer has drastically 
changed over the last decade. The progress in sequencing technologies has shown that cancer-associated 
loci cannot only be in protein-coding regions, but also in non-coding regions (Schmitt & Chang, 2016). 
LncRNAs are studied widely in solid tumors, especially in breast cancer (Soudyab, Iranpour, & Ghafouri-
Fard, 2016; Xu, Kong, Chen, Ping, & Pang, 2017). In breast cancer, the over expression of lncRNAs 
HOTAIR promotes the metastasis by epigenetically silencing the developmentally essential genes in the 
HOXD cluster (Gupta et al., 2010). LncRNAs are thus known as the functional transcripts which add on 
to the significant characteristics of cancer, and therefore they can be potential therapeutic targets. The 
comprehension of lncRNAs with the development of sequencing technologies has enabled lncRNAs in 
detailing their expression, function, and distribution in the human genome. 
By now, we know that lncRNAs are a highly heterogeneous group of transcripts, which modulate gene 
expression using different mechanisms. Accordingly, some of them are found to be differentially 
expressed in various solid cancers, and they are directly linked to the conversion of healthy cells into 
tumor cells and thus represent an important factor of tumor biology. 
1.10  Hallmarks of cancer 
According to Hanahan and Weinberg, in their paper, “The hallmarks of cancer.” they proposed six 
hallmarks which collectively contribute towards the fundamental principle of malignant transformation 
(D Hanahan & Weinberg, 2000). These basic hallmarks are: 




• Insensitivity to growth inhibition 
• Avoiding apoptosis 
• Uncontrolled proliferation 
• Promotion of angiogenesis 
• Tissue invasion and metastasis 
Two additional emerging hallmarks according to 2011, are the capability to modify or reprogram, cellular 
metabolism in order to most effectively support neoplastic proliferation. The second one is cancer cells 
to evade immunological destruction, in particular by T and B lymphocytes, macrophages, and natural 
killer cells (Douglas Hanahan & Weinberg, 2011). 
1.11  LncRNAs in cancer hallmarks 
Self-sustained growth signaling: LncRNAs promote self-sufficiency by activating/stabilizing the 
expression of growth factor receptors thereby enhancing signal transduction in response to the growth 
signals/ factors. There are multiple lncRNAs serve as receptors. For example, lncRNA SRA, serves as a 
scaffold to stabilize estrogen receptor (Lanz et al., 1999). In addition to activating signal receptors, some 
lncRNAs affect proliferation by regulating receptor abundance lncRNA, for example, lncRNA PVT1 
(Zhou, Chen, Feng, & Wang, 2016). 
Insensitivity to growth inhibition: LncRNAs can regulate growth inhibition mostly by influencing the 
tumor suppressor genes that regulate cell cycles such as cyclins, CDK inhibitors, and tumor suppressor, 
P53 (Kitagawa et al., 2013). The process is mainly by repression of the transcription through PRC 
complex. Certain other lncRNAs regulate the expression of tumor suppressor gene by influencing various 
parts of transcription and translation. The scaffolding of transcriptional factor complexes can influence 
transcription initiation. Finally, the transcript stability and translation can be modulated post-
transcriptionally by reducing the role of miRNAs. For example, PTENP1 is acting as competitive 
endogenous RNA to inhibit miRNAs repression of PTEN, tumor supressor gene (L. Yang, Wang, Shen, 
Feng, & Jin, 2017). 
Avoiding apoptosis: Apoptosis refers to the controlled cell death, one of the key pathways to control in 
carcinogenesis. Reports showed that some lncRNAs act on regulation of transcription of the essential 
apoptosis gene. LncRNA INXS is an example, it is expressed from the intron of B-cell lymphoma-extra 




BCL-XS (Deocesano-Pereira et al., 2014). Another discovery is lncRNA PRAL, which induces apoptosis 
by stabilizing the complex between heat shock protein 90 (HSP90, assist protein to fold correctly) and 
P53. However, their mechanism of action remains unknown. 
Uncontrolled proliferation: Proliferation is the potential of cancer cells for limitless replication. The 
maintenance of telomeres as nucleo-protein structures that stabilizes ends of chromosomes is a key factor 
for the proliferation of cancer cells. In the dividing cells, the telomeres shorten, so it takes a 
ribonucleoprotein complex telomerase to elongate the telomeric repeats through reverse transcription of 
an internal template RNA. The shortening of telomeres induces the production of lncRNA Telomere 
repeat-containing RNA (TERRA) (Redon, Reichenbach, & Lingner, 2010), which is transcribed from the 
sub-telomeric regions. Under normal conditions, TERRA inhbit its own expression through chromatin 
modifications, but recruits protein complexes for homology-directed repair of shortened or damaged 
telomeric sequences when activated. 
Promotion of angiogenesis: Angiogenesis is the process of formation of new blood cells from existing 
ones. Angiogenesis can be a support for tumor cells to grow and migrate (Folkman, 1974). There are a 
few lncRNAs which regulate nutrient supply to tumor, mostly by regulating the expression/ function of 
VEGF (vascular endothelial growth factor), which is essential for the production of blood vessels. 
LncRNAs MIAT are reported to transcriptionally regulate VEGF. Knockdown of MIAT showed that it is 
required for the repression of VEGF, which resulted in microvascular dysfunction and decreased 
metastasis (B. Yan et al., 2015). 
Tissue invasion and metastasis: Metastasis is the process by which cancer cells spread to distant parts 
of the body from its tissue of origin. Several reports showed that multiple lncRNAs increase the capacity 
of the cancer cell to invade new sites and therefore facilitate metastasis. MALAT1 is an example lncRNA 
which facilitates the invasiveness of cancer cells in colorectal and nasopharyngeal carcinoma (M. H. 
Yang et al., 2015). Other example is, lncRNA, lincRNA-RoR which acts as a “sponge” for miR-145 
which regulates ADP-ribosylation factor 6, a protein involved in the invasion of breast cancer cells 
(Eades et al., 2015). 
1.12  Translational Implications of lncRNAs in cancer 
Cancer therapy is facing the challenge of cancer cell specificity and delivering anti-cancer drugs without 
interfering with normal cells functions. Profiling the differential abundance of lncRNAs may assist 




Du, 2013). Moreover, lncRNAs are detectable from minute amounts of biological fluids like urine, blood 
and serum using qRT-PCR amplification making it as a diagnostic marker (Geng, Xie, Li, Ma, & Wang, 
2011). For example, the highly up-regulated in liver cancer hepatocarcinoma-associated lncRNA 
(HULC) can be readily detected in the blood of HCC patients using qRT-PCR (Panzitt et al., 2007). 
Another example is PCA3, is a lncRNA that is prostate-specific and markedly over expressed in prostate 
cancer. Although its biological function is unclear, lncRNA PCA3 can be utilized as a biomarker in 
diagnostic assays for prostate cancer (Van Gils et al., 2007). 
Finally, lncRNAs are an attractive therapeutic option considering their tissue-specific or cell-specific 
expression pattern. For example, the expression of the lncRNA, H19 elevated in a wide range of human 
cancers. A plasmid, BC-819 (DTA-H19), has been developed to make use of this tumor-specific 
expression of H19 (Smaldone & Davies, 2010). Intra-tumoral injections of this plasmid induce the 
expression of high levels of diphtheria toxin specifically in tumor, resulting in tumor size reduction in 
human trials. Recent studies have yielded promising results in a wide range of solid cancers including, 
colon, and bladder, pancreatic and ovarian cancers. Therapeutic application of lncRNAs provides an 
attractive treatment prospect, although still more intensive research is required. The current era of 
lncRNA research is giving rise to a new field within the biology of hematopoiesis and blood diseases. 
1.13  Leukemia 
Leukemia is mainly diagnosed based on the number of blasts typically quantified by blood tests. The 
exact cause of leukemia is still unknown. However, it seems to develop from a combination of genetic 
and environmental factors. Studies indicate both inherited, and environmental factors are involved in the 
formation of leukemia. 
Acute leukemia is a type of leukemia occurring mostly in bone marrow characterized by the massive 
accumulation of immature white blood cells. These immature white blood cells are also known as blasts 
or leukemic cells. For instance, the risk factors are smoking, ionizing radiation, prior chemotherapy, and 
Down syndrome. The environmental factors including, artificial ionizing radiation, chemicals and 
smoking influences the genome which leads to different genetic factors leading to leukemogenesis. The 
genetic factors of leukemogenesis are described in the following session. 
1.13.1  Leukemogenesis 
The occurrence of leukemia is due to the uncontrolled proliferation of hematopoietic stem cells in the 




2014). The most common alterations in genes regulating blood cell development or homeostasis are the 
following: 
DNA translocations: Translocations means that a part of one chromosome breaks off and becomes 
attached to a different part of the same chromosome or in a different chromosome altogether.  
Inversions, or deletions: The deletions of the transcription factors which are essential for the normal 
hematopoietic development. Hematopoietic development is a normal process of immature blood cell 
development into all type of mature blood cells, including white blood cells, red blood cells, and platelets. 
For example, deletion of IKZF1, which is linked to crucial function in hematopoietic system its loss of 
function leads to lymphoid leukemias. 
Mutations: The alteration of the nucleotide sequence of the genome. In leukemogenesis, two types of 
mutations must occur for leukemia formation one is, a mutation which improves hematopoietic cells 
ability to proliferate which includes FLT3 and KIT. The second type is a mutation that prevents the cells 
from maturing including CBFB-MYH11. 
1.13.2  Major types of Leukemia 
Based on the type of bone marrow cells that are affected, leukemia can be classified into different types 
(Table 1.13.1). Leukemia can arise in two different types of white blood cells, myeloid and lymphoid 
white blood cells. When leukemia is affected in lymphoid precursor cells it is called acute lymphoblastic 
leukemia, and when affected in myeloid cells, it’s classified as myeloid leukemia. 
Table 1.13.1: The types of leukemia 
Types of leukemia Definition 
Acute Myeloid Leukemia (AML) AML arose from immature myeloid cells. Myeloid cells are the cells that 
make white blood cells (other than lymphocytes), red blood cells, 
megakaryocytes (platelet-making cells). 
Acute Lymphocytic Leukemia (ALL) ALL arises from the immature forms of lymphocytes, thus known as 
lymphoid or lymphoblastic leukemias. This is one of the most common 
leukemia in children and affects adults. 
B-cell Acute Lymphoid Leukemia 
(BCP-ALL) 
BCP-ALL is a heterogeneous disease associated with different patterns 
of molecular changes including protein fusions, mutations and copy 
number variations 
T-cell precursor lineage (T-ALL) T-ALL is biologically distinct from its counterpart, B-ALL. T-ALL 
shows a different dynamic form of disease response. 




(CML) granulocytic cell line. It is a myeloid proliferative disorder. 
Chronic Lymphocytic Leukemia 
(CLL) 
 CLL often occurs in adults above or equal to 55 years old. In very few 
cases it affects young adults. 
Table 1.13.1: The table contains the different types of leukemia based on their lineage and the pace of occurrence 
(Vardiman et al., 2009). 
1.14  B-cell Acute Lymphoid Leukemia (BCP-ALL) 
The present thesis is focused on B-cell based acute leukemia affecting the lymphoid cell, B-cell precursor 
ALL. B-cell precursor acute lymphoblastic leukemia (BCP-ALL) remains a major cause of death in 
pediatric patients. BCP-ALL is a heterogeneous disease associated with different patterns of molecular 
changes including protein fusions, mutations and copy number variations. The major chromosomal 
alterations are aneuploidy, the abnormal number of chromosomes, and chromosomal rearrangements, 
which results in oncogene deregulation or expression of chimeric fusion genes (Mullighan, 2012). 
1.15  The subtypes of BCP-ALL 
BCP-ALL comprise of multiple subtypes which are defined based on the structural chromosomal 
alterations, Somatic mutations and DNA copy number alterations that contribute to leukemogenesis. The 
alterations are prevalent in all age groups and so as the various subtypes (Figure 1.15.1). Identification 
of these subtypes is essential for diagnosis, risk classification, and, for some lesions, it enables the 
development of targeted therapy. 
The subtypes investigated to profile their lncRNAs based molecular signature in this project are described 




1.15.1  Double homeobox 4 (DUX4) BCP-ALL subtype 
The DUX4 is a recently discovered subtype within BCP-ALL which is characterized by the IGH-DUX4 
gene fusion and is prevalent in both adult and pediatric patients of BCP-ALL. The existence of DUX4 
subtype was first hinted in a microarray dataset study on childhood BCP-ALL patients, where a subset 
of cohort displayed a unique expression profile outside the well-established subtype. The same group 
further performed an integrated genomic analysis on 277 ALL cases to investigate the genetic basis of 
this novel subtype (Yeoh et al., 2002). A recent study (Clappier et al., 2012) revealed that around 50-70% 
of these cases showed deletions in the intragenic region of erythroblast transformation (ETS)-specific-
related gene (ERG). The ERG, a gene coding for a transcription factor in ETS family, with important 
functions in hematopoiesis. The genomic aberration observed was approximately non-existent in other 
BCP-ALL cases. Later other studies found that deletion of ERG is associated with CD2 expression and 
Ikaros family zinc finger protein 1 (IKZF1) deletions with a positive clinical prognosis, which is 
 
Figure 1.15.1: Subtypes in ALL across different age groups. 





otherwise associated with a poor prognosis (Harvey et al., 2010). 
In the vast majority of cases at least one truncated copy of the DUX4 gene is usually located within 
subtelomeric region and is inserted (D4Z4 repeat array on chromosome 4q and 10q) into the 
Immunoglobulin heavy (IGH) locus. ERG-DUX4 is a less common variant involved in the insertion of 
DUX4 gene into an intron of the ERG gene. In both variants (IGH-DUX4 and ERG-DUX4) a 3’ truncated 
DUX4 transcript with nucleotides added from non-coding regions of IGH or ERG is expressed, resulting 
in a DUX4 protein replaced with random 0-50 amino acids from non-coding partner genes in the same 
region. The relocation of DUX4 attributes to the truncation of C terminal of DUX4 protein and increased 
stability of DUX4 mRNA due to the presence of poly-A signals in the partner region (Lilljebjörn & 
Fioretos, 2017). 
The DUX4 transcription factor is normally expressed in germinal tissues, and its expression is partially 
regulated by the repeat structure of D4Z4 domains, where a certain number of repeats are needed to 
preclude the luxated DUX4 expression. Currently, it is unclear how the expression of DUX4 fusions 
contributes to leukaemia development. In pediatric BCP-ALL 4-5% of the cases harbour DUX4 
rearrangements, making it the sixth largest subtype of childhood BCP-ALL, slightly larger than Ph-
positive subtype (Lilljebjörn & Fioretos, 2017). 
Despite the common ERG deletions, DUX4-rearranged cases might also harbour other common 
aberrations associated with various other subtypes of BCP-ALL, such as deletions in targeting cell cycle 
regulator genes CDKN2A and CDKN2B and lymphoid transcription factor genes such as IKZF1 and 
PAX5. 
1.15.2  Philadelphia positive (Ph-pos) BCP-ALL subtype 
The Philadelphia chromosome is a result of the molecular fusion between the ABL gene, which is located 
on the chromosome 9 with BCR gene located on the chromosome 22, which results in a fusion protein 
called BCR-ABL (Liu-Dumlao, Kantarjian, Thomas, O’Brien, & Ravandi, 2012). BCR-ABL encodes an 
oncogenic protein with a constitutively activated tyrosine kinase function. The prevalence of BCR-ABL 
positive ALL, also called Philadelphia (Ph)-positive, increases with age and occurs in up to 50% of ALL 
diagnosed in individuals ≥50 years old (Liu-Dumlao et al., 2012). The Ph-positive ALL is characterized 
by poor response to therapy, short remission duration and poor survival. The occurrence of BCR-ABL 




1.15.3  Philadelphia-like (Ph-like) subtype 
Recently a high-risk subgroup of BCP-ALL called Philadelphia-like (Ph-like) has been discovered in 
pediatric and adult patients (Herold & Gökbuget, 2017). The Ph-like blasts harbor a similar gene 
expression profile as BCR-ABL1 positive ALL patients but lack the BCR-ABL1 translocation (Tran & 
Loh, 2016). However, instead of BCR-ABL like gene fusion, such patients harbor a wide range of genetic 
alterations activating tyrosine kinase signaling. Most common genomic features of these patients are 
deletions of IKZF1 transcription factor and genetic alterations deregulating cytokine receptor and 
tyrosine kinase signaling (Tran & Loh, 2016). These include translocations and mutation of CRLF2 of 
approximately 50%, 12% translocations of ABL-class tyrosine kinase genes, 7% of rearrangements of 
JAK2 and 3-10% of the erythropoietin receptor gene (EPOR). Furthermore, 11% mutations activating 
JAK-STAT signaling and RAS signaling (NRAS, KRAS, PTPN11, and NF1, 6%) and less common kinase 
alterations (FLT3, NTRK3, BLNK, TYK2, and PTK2B). Kinase fusions continue to keep an intact 
tyrosine kinase domain and typically show a constitutive kinase activation. There is no significant 
difference in frequency of kinase subtypes across different age groups, apart from EPOR and JAK2 
rearrangements which are increased in adult Ph-like ALL. Cytokine receptor-like factor 2 (CRLF2) is 
also known as the thymic stromal-derived lymphopoietin receptor (TSLPR) that forms a heterodimeric 
receptor with the interleukin-7 receptor a chain (IL7Ra) for thymic stromal lymphopoietin (TSLP). 
Dysregulations of CRLF2 includes its translocation into the immunoglobulin heavy chain locus (IGH-
CRLF2) and less common point mutations. All these rearrangements are most common in Ph-like and 
Down syndrome-associated ALL and are dependent on age. For instance, with P2RY8-CRLF2 associated 
with young age and I-CRLF2 associated with older age and Hispanic ancestry. Flow cytometric 
immunophenotyping detects CRLF2 and is over expressed on the leukemic lymphoblasts. CRLF2 
rearrangements are associated with poor prognosis in most studies, particularly in cases with concurrent 
IKZF1 alteration (Iacobucci & Mullighan, 2017). 
The common therapies have shown efficacy in per-clinical models that targets JAK-STAT, PI3K/mTOR, 
and BCL2 signaling alone or its combinations. Another major genetic subgroup within Ph-like ALL 
involves ABL class of rearrangements. For example, fusions to ABL1, ABL2, CSF1R, PDGFRA or 
PDGFRB that are all targetable by inhibitors of ABL1, such as imatinib and dasatinib. Like Ph-positive 
ALL, Ph-like ALL is also associated with high-risk clinical features such as poor response to induction 
chemotherapy, elevated minimal residual disease (MRD) levels, and poor survival. According to world 
health organisation’s classification of myeloid neoplasms in 2016, BCR-ABL1–like or Ph-like ALL acute 




an unfavourable prognosis and reactivity towards Tyrosine Kinase Inhibitor (TKIs). Ph-like ALL 
increases with age and varies from 10% in standard-risk childhood ALL to greater than 20% in adult 
ALL, with a peak prevalence of 27.9% in young adults (age 21 to 39 years) (Iacobucci & Mullighan, 
2017). 
1.15.4  Near haploid/High hyperdiploid (NH-HeH) BCP-ALL subtype 
The abnormal chromosomal number in ALL defines distinct subtypes with different response to 
treatment. High hyperdiploid is a subtype defined based on cytogenetic nomenclature as chromosomal 
count between 47 and 57; the definition criteria are universally accepted. High hyperdiploid is one of the 
common childhood malignancies comprising 30% of all pediatric B cell–precursor ALL. Molecularly, 
high hyperdiploid ALL is characterized by massive aneuploidy (abnormal number of chromosomes), 
authenticating a nonrandom gain of chromosomes. For example, some or all of +X, +4, +6, +10, +14, 
+17, +18, and +21 and other trisomies have been reported. However, the pathogenetic phenomenon of 
chromosomal gains remains poorly understood, but it generally is believed that gene dosage effects are 
of significance (Chilton et al., 2014). Genetic abnormalities like driver fusion gene is not observed in the 
vast majority of high hyperdiploid ALL cases. However, there is a possibility that there is yet unidentified 
primary aberrations present due to the low resolution of most genetic screening techniques. Previously 
such concealed events have been reported in aneuploid tumors, for example, the identification of 
structural dysregulation resulting in rearrangements of cytokine receptor-like factor 2 (CRLF2) in a large 
number of ALL patients with Down syndrome and microdeletions leading to the transmembrane protease, 
serin 2 (TMPRSS2)/v-its erythroblastosis virus E26 oncogene homolog (ERG) hybrid gene in prostate 
cancer (Mullighan et al., 2009). Profiling of a fusion gene in high hyperdiploid ALL would be of prima 
facie clinical importance, which may perhaps simplify the diagnostic procedures and hence provide novel 
treatment options. Clinical features of high hyperdiploid ALL was associated with a relatively low WBC 
count and a B-cell precursor immunophenotype. The prognosis of five-year overall survival rates (OS) 
is close to 90%. 
Recent genome-wide association studies by two independent groups reported linkage to a locus in the 
gene AT rich interactive domain 5B (ARID5B) at the locus 10q21.2, however, it is unclear how this 
region affects the risk of developing high hyperdiploid childhood ALL (Studd et al., 2017) ⁠. Despite a 
favourable prognosis in high hyperdiploid childhood ALL, ~20% of the patients suffer a relapse, and 
10% give in to the disease (Paulsson et al., 2010). The finding of extra recurrent changes could subserve 




In contrast, Near-haploid ALL is much rarer (<1%) ALL subtype defined based on the cytogenetic 
nomenclature of the 23-29 chromosome, with poor outcome (Safavi & Paulsson, 2017). The Near-
haploid is mainly reported in children and adolescents. Lately, some adult cases are also reported. 
Because of the rarity of near-haploid ALL subtype, relatively very few studies have focused on this 
molecular subtype and no studies on lncRNAs are reported to this date. 
In this present study, we are focusing on the three major subtypes defined above namely, DUX4, Ph-like 
and NH-HeH. In addition to the subtypes mentioned above, BCP-ALL has additional subtypes which are 
described briefly in the following session. 
1.15.5  Pre-B-cell leukemia transcription factor 1 (PBX) fused 
The translocation resulting in the Transcription factor 3 (TCF3) - PBX1 fusion occurs in approximately 
5% of childhood to 6% of adult BCP-ALL cases. With the rise of novel therapies, it is now associated 
with a favorable outcome (Diakos et al., 2014). 
1.15.6  Myocyte enhancer factor 2D (MEF2D) fused 
MEF2D and zinc finger 384 (ZNF384) rearrangements characterize distinct B-ALL subtypes, accounting 
for approximately 3% to 4% and 3% of pediatric patients and approximately 6% and 7% of adult patients, 
respectively. The MEF2D related fusions are recently identified B-ALL subtype with relatively worse 
survival (Zhaohui Gu et al., 2016). 
1.15.7  Mixed lineage leukemia (MLL) translocations 
Mixed lineage leukemia (MLL/KMT2A) gene are common in young patients and are generally 
associated with poor clinical outcomes. The molecular biology of MLL fusion genes remains 
incompletely characterized and is complicated by the fact that more than 100 different partner genes have 
been identified in fusions with KMT2A gene (also known as MLL) rearrangements, particularly the t 
(4;11) (q21;q23) translocation, are most frequent in infants (1 year of age) and are associated with poor 
outcome (Winters & Bernt, 2017). 
1.16  LncRNAs in leukemia 
1.16.1  LncRNAs in normal hematopoiesis 
Hematopoiesis is a process of formation of blood cellular components. All blood cells are derived from 
hematopoietic progenitor cells or hematopoietic stem cells. Hematopoietic progenitor cells are found in 




mainly associated with the blood cell development (B. W. Han & Chen, 2013) (Figure 1.16.1 A). Notably, 
two lncRNAs are associated with early blood cell development from hematopoietic progenitor cells. The 
first example is lncRNA HOX antisense intergenic RNA myeloid 1 (HOTAIRM1), in the intergenic region 
of the HOXA cluster and transcribed in the antisense direction. HOTAIRM1 renders the expression of 
several genes that are important for myeloblasts differentiation including HOXA1 and HOXA4, which 
encode key transcription factors in hematopoiesis. The second example is lncRNA EGO, which is a 
conserved lncRNA transcribed antisense to ITPR1 and regulates the development of eosinophils (a type 
of white blood cell). Other lncRNAs which are related to the terminal differentiation of hematopoietic 
cells are ncRNA repressor of the nuclear factor of activated T cells (NRON), thymus-specific non-coding 
RNA (Thy-ncR1), and nettie Salmonella pas Theiler's (NeST), which regulate the localization, 
degradation, and expression of pivotal gene products, orderly. Hence, deficiency of any hematopoiesis-
related lncRNAs blocks differentiation and stimulates the apoptosis of blood cell progenitors, 
deregulation of these lncRNAs might contribute to blood diseases, especially those associated with 
ineffective blood cell production, such as myelodysplastic syndrome (MDS) and anemias. Depending on 
the changes in lncRNA regulation, dys-regulation of these could also result in the oncogenic growth of 





1.16.2  LncRNAs in malignant hematopoiesis 
Compared to solid cancers, little is known about lncRNAs in hematopoietic malignancies, especially in 
ALL subtypes. However, a few lncRNAs (Table 1.16.2, Figure 1.16.1B) have been identified in the 
context of leukemia and been directly involved in the tumorigenic processes of blood cell cancers 
(Hughes, Salvatori, Giorgi, Bozzoni, & Fatica, 2014). The before mentioned HOTAIRM1 and ANRIL are 
two well-studied lncRNAs in malignant hematopoiesis. They might serve as potential prognostic 
candidates for leukemia due to their leukemic specific expression pattern. Increased ANRIL expression 
has been reported increased in many AML and ALL patients (Yu et al., 2008), whereas MEG3 and BIC 
 
Figure 1.16.1: LncRNAs in normal and malignant leukemia 
LncRNAs involved in the progression of multiple chromatin remodelling pathways and are involved in hematopoiesis 
and leukemogenesis. A. In healthy blood cells, lncRNAs are involved in recruiting epigenetic regulatory protein 
complexes, including chromatin remodeling enzymes to specific genetic target sites, by inhibiting or promoting 
mRNA translation or degradation, or by promoting or inhibiting the translocation of transcription factors into the 
nucleus, in normal hematopoiesis. B. In malignant cells, abnormally expressed lncRNAs lead to the deregulation of 
hematopoietic factors, resulting in an aberrant expression profile of oncogenes and tumor suppressors that leads to 




expression were decreased in myeloid leukemia (Eis et al., 2005) and increased in B cell lymphoma, 
respectively. However, there are no lncRNAs reported as a leukemic prognostic marker. 
The TP53 related lncRNAs such as MEG3, lincRNA-p21, are tumor suppressors whereas ANRIL is 
reported to function as tumor-promoting lncRNA. Several other lncRNAs have been shown to regulate 
key transcriptional factors that function in normal hematopoiesis, any dysregulation to these lncRNAs 
could contribute to malignant hematopoiesis. Some lncRNAs control other genes which participate in or 
regulate cancer-associated pathways. For instance, DLEU1 and DLEU2, which are frequently deleted in 
Chronic Lymphoblastic Leukemia (CLL). In some CLL patients, these lncRNAs were shown a consistent 
alteration in methylation with reduced expression at transcriptional start site (TSS). In addition to that, 
they are correlated with transcriptional deregulation of the neighboring genes and reduced expression of 
genes involved in NF-kappa beta pathway (B. W. Han & Chen, 2013). 
These lncRNAs associated with the tumor suppressor TP53, which act as regulators of the cell cycle or 
apoptosis and signaling pathways that are involved in leukemia hint that lncRNAs might take part in 
leukemogenesis either as tumor suppressors or as tumor promoters. Any dysregulation of these lncRNAs 
or others might furnish to the aberrant activity of leukemia-related genes, and that would further lead to 
malignant hematopoiesis. Specific lncRNAs having an association with particular forms of leukemia 
suggests that those lncRNAs may be useful for categorizing leukemia subtypes, and the possibility for 
therapeutic intervention may exist (B. W. Han & Chen, 2013). 
By now we know that BCP-ALL is a heterogeneous blood cancer with multiple molecular subtypes, and 
a high relapse rate. Despite the improvements, we are still far from having a complete understanding of 
the rationale behind these subtypes. LncRNAs have emerged as a novel class of RNAs with diverse 
mechanisms in cancer progression and development. Recently, genome-wide association studies 
(GWAS) have unveiled that more than 80% of cancer-associated single-nucleotide polymorphisms occur 
in the non-coding part of the genome (Cheetham, Gruhl, Mattick, & Dinger, 2013). This suggests that a 
significant fraction of the genetic etiology of cancer is related to lncRNAs. 
Moreover, the association of lncRNAs with various hallmarks of cancer in different cancer types shows 
that lncRNAs can account for cancer heterogeneity and can be used as an independent prognostic factor. 
However, lncRNAs defining molecular subtypes of BCP-ALL and their potential functions and 
epigenetic regulation are not portrayed yet. All previously reported ALL subtypes are well characterized 
and documented for their mRNA based molecular signature (Boer et al., 2015; Nordlund et al., 2012). 




heterogeneity thus remains as a significant objective in improving diagnosis and therapy. The 
extraordinary advancement in sequencing technology allowed the detection of low abundance transcripts 
on a genome-wide scale. Majority these studies explored the role of a specific single lncRNAs (Ghazavi 
et al., n.d.). However, these lncRNAs have not been precisely related to molecular pathways, and their 
functions have not been investigated. The long non-coding RNA based molecular signature behind these 
subtypes are less studied or characterized. Comprehensive characterization of the landscape of lncRNAs 
in a BCP-ALL subtype has not been achieved because most genome-wide studies have used micro-arrays, 
which have the disadvantage of being biased toward the inclusion of probes that map to the known 
protein-coding and lncRNAs transcriptome. Therefore, a comprehensive genomic delineation of 
lncRNAs alterations in multiple BCP-ALL subtypes not only is urgently needed but may lead to new 
diagnostic and therapeutic strategies for leukemia. 
Table 1.16.2: LncRNAs which are reported as putatively involved in leukemia. 
LncRNA Size Genomic location 
MEG3 ~1.6 Kb 
Intergenic 
 
HOTAIR 2.2 kb Antisense between HOXC11 and HOXC12 
ANRIL ~3.9 kb Antisense of CDKN2B 
Mira 789 not Between Hoxa6 and Hoxa7 
LincRNA-p21 ~3.1 kb Upstream of CDKN1A 
DLEU1 DLEU2 0.9 kb Adjacent to miR-15 and miR-16 family 
XIST ~19kb Intergenic 
HOTTIP ~3.8 kb Bidirectional transcript with HOXA13 
Table 1.16.2: The table defines the lncRNAs associated with malignant hematopeosis and their genomic target of 
action. Adapted from (82). 
1.17  The aim of the project 
The overall aim of this thesis was to profile relapse and subtype-specific lncRNAs in three significant 
subtypes of BCP-ALL namely, DUX4, Ph-like and NH-HeH to deepen our understanding of the 
functional role of lncRNAs in molecular processes in BCP-ALL. Furthermore, to investigate lncRNAs 
involvement in classifying the molecular subtypes of BCP-ALL. Finally, to investigate epigenetically 
regulated lncRNAs within the three subtypes. 
In order to define lncRNAs within the BCP-ALL subtypes, we performed the integrative bioinformatics 
analysis on the RNA-seq and DNA methylation datasets of 82 BCP-ALL patient samples from diagnosis 




• Construct BCP-ALL subtype-specific and relapse-specific lncRNAs signatures 
• Validate the subtype-specific lncRNAs of BCP-ALL on a independent cohort 
• Define the potential functions of subtype-specific and relapse-specific lncRNAs 
• Explore DNA methylation patterns of lncRNAs within the three BCP-ALL subtypes 
• Unravel epigenetically altered lncRNAs within each subtype. 
Overall, our data uncover the distinct mechanism of action of lncRNAs in BCP-ALL subtypes and 
defining how lncRNAs are involved in the pathogenesis of diseases as well as their relevance in the 





Chapter 2.  Materials and methods 
2.1  Patient datasets 
The patients used in the current study lacked routinely tested fusion genes (BCR-ABL, MLL 
translocations, ETV6-RUNX1) and were evenly distributed between pediatric and adult patients with 
early and late relapse. The sample was retrieved at initial diagnosis (ID), and relapse (REL) with the 
requirement of a minimal residual disease (MRD) level at complete remission below 0.01. The study 
group consisted of 45 patients with ID (40 samples) and matched REL (42 samples) stages of B-cell 
precursor ALL patients from German Multi-center Study Group ALL (GMALL) and Augmented Berlin-
Frankfurt-Munster (BFM) trials. As the clinical protocol for adult and pediatric patients relapse time were 
different, the samples have been selected to evenly distribute into the categories of early relapse (ER; 
time of REL < 700 days) and late relapse (LR; time of REL => 700 days). Based on mutations, DNA 
methylation, translocations, and insertions or deletions these samples were further categorized into three 
subtypes (Table 2.1.3). These subtypes are, DUX4 (n = 23) (IGH-DUX4 fusions), Philadelphia-like (Ph-
like (n = 21), and Haploid/High Hyperdiploidy (NH-HeH) (n = 16), low-hypodiploid (LH, n = 6) others 
(n = 16). There were 16 other samples are un-assigned because they do not belong to any of these 
subtypes. Patients and their clinical features are defined briefly in Table 2.1.3, which include their 
subtypes. All patients were treated in population-based German study trials (GMALL for adult and BFM 
for pediatric patients). All patients gave written informed consent to participate in these trials according 
to the Declaration of Helsinki. The studies were approved by the ethics board of Charité, Berlin. 
Table 2.1.3: Patient clinical information and their subtypes. 
Subtype Patient Median Age Mean time to relapse 
(months) 
DUX4 Adult 46 26 
Pediatric 9 83 
LH Adult 37 51 
NH-HeH Adult 22 40 




Ph-like Adult 42 59 
Pediatric 14 65 
Others Adult 33 71 
Pediatric 10 25 
Table 2.1.3: The table represents the patient samples (n = 82) used in this study, along with their defined subtypes and 
the mean of the months they were in complete remission, and their median age. Unassigned samples are hereafter 
refereed as others. 
2.2  Major steps in RNA-Seq and DNA methylation array data analysis 
2.2.1  RNA -Seq dataset preparation 
RNA-Seq data preparation consists of following steps: we isolated total RNA from bone marrow 
mononuclear cells (MNCs) from ID, and REL conditions of BCP-ALL patients. We used Trizol reagent 
(Life Technologies, Grand Island, NY) for isolation and followed the manufacturer's protocol with minor 
modifications. Then the amount of RNA degradation is checked with gel, and capillary electrophoresis 
and an RNA integrity number (RIN) was assigned to all the samples. The samples with RIN greater than 
seven were then used for further steps. 
RNA seq was performed on the Illumina HiSeq4000 platform. Paired-end reads were obtained from both 
ends of a fragment (paired-end sequencing). The paired-end reads were 101 base pair in length and bases 
with Phred +33 quality score were used further for analysis. These Phred quality scores Q are set by the 
Base Callers and are defined as Q = −10log10 (P), where P is the probability of the base call being 
incorrect. This value is an assigned quantity value to bases in DNA sequencing trace file by PHRED 
software. For example, if Phred assigns a Q score of 30 (Q30) to a base, this is equivalent to the 
probability of an incorrect base call, 1 in 1000 times, which means that the base call accuracy (that is, 
the probability of a correct base call) is 99.9%. These runs were performed in the high throughput 





We followed the alignment-counting work-flow (Figure 2.2.1) in our analysis pipeline. In order to 
account for the technical constraints of the tools, before finalizing each tool and analyzing method used 
in this project we compared the performance and results with respect to other tools This analysis helped 
us to finalize the most optimized and suitable tools for our dataset and analysis. The tools used for each 
analysis and their versions are detailed in table 2.2.4. The reason behind the selection of each tool is 
defined in their respective sessions. All the analyses were performed in the UNIX environment (Ubuntu 
14 LTS). The main steps involved in both dataset analysis is described in the following section. 
Table 2.2.4: Bioinformatics tools and software used in analyzing RNA-Seq and DNA-methylation 
datasets 
The table represents the tools and software and the programming languages we used in this thesis. 
Tools Description Version 
RNA-Seq data analysis 
Cutadapt Trimming and removing low-
quality reads 
V1.17 
RNA-Seqc Quality metric NA 
Star-align RNA-seq alignment V2.4.0.1. 
StrinTie/PreDE Transcriptome assembly read 
quantification 
v1.3.1 
LIMMA Voom Differential expression NA 
 
Figure 2.2.1: The global bioinformatics pipeline and the samples used in the analysis. 
The diagram defines the DNA methylation and RNA-seq work-flow and important methods and tools in the pipeline. 





GREAT Cis and trans genes located 3.0.0 
GeneSCF Functional enrichment v. 0.1 
DNA methylation analysis 
Bumphunter Differential Methylation 
analysis 
NA 
HOMER/annotationPeaks.pl Annotation of files NA 
Additional software and programming languages 
R-Bioconductor version (3) 
SHELL and BASH scripting 
Python 2 and 3 
Pandas, Scify, numpy, matalblibplot, Seaborn 
Table 2.2.4: The table represents the bioinformatics tools used in the analysis and their versions. Additionally, the 
R-Bioconductor packages, and the scripting languages used in this thesis. 
2.3  RNA-Seq data analysis 
2.3.1  Preprocessing the Fastq files 
The sequence reads from the Illumina HiSeq4000 machine came out in fastq (. fq) formatted files. The 
FASTQ format was first widely used in the Sanger Institute; it stores both biological sequence and its 
corresponding quality scores in the text-based format in the single file. 
The first step of RNA-seq data analysis is to per-process the FASTQ file by measuring specific quality 
control metrics. The measured quality metrics are low-quality reads, followed by removing the 3’ adapter 
sequence. The adapter sequence was from Illumina TrueSeq, we used the cutadapt tool to perform the 
trimming and removal of low-quality reads with the following parameters: 
For removing the low-quality reads from the end of read sequences we used, -quality-base = 33 (retains 
the Phred 33 quality bases) parameter with a cut-off of 5 (--quality-cutoff = 5). The read sequence which 
retained a length of >= 25 base pair, were filtered using the -m 25 parameters. The adapter sequences 
were removed by adapter = [TACACTCTTTCCCTACACGACGCTCTTCCGATCT, 
GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT] parameter. The resulted FASTQ files were 
then further used for downstream analysis. 
2.3.2  Read Alignment 
Read alignment is the first, the most time-consuming step in RNA-Seq data analysis. The trimmed and 




a mapping algorithm, STAR with options: -twopassMode Basic –sjdbOverhang and the Gencode (a 
project for integrated annotation of gene features) comprehensive GTF files as reference transcriptomes 
(gencode.v19.annotation.gtf.gz,v19) along with other default parameters. The STAR-align performed the 
read alignment steps in two runs, explained as follows: 
In the 1st pass, STAR allows mapping to a genome with unknown junctions and extracts the novel read 
junctions, then insert them into the genomic index. The 2-pass alignment is a more advanced mapping 
strategy for a more accurate spliced alignments, where the reads are then re-mapped using the 
GENCODE annotation file, from the provided novel junctions reads. These novel junction reads were 
detected during the 1st pass alignment process. The Splice junctions are the exon-intron junctions, where 
the splicing takes place. The output from STRA-align tool was aligned FASTQ files in Sequence 
Alignment/Map (SAM) format. The read SAM format files sorted by coordinate were produced after the 
alignment process for each patient samples. 
The SAM file is a TAB-delimited text file which consists of a header session and alignment session. 
However, SAM files are big and consumes more computational resource, mainly disk space, therefore 
they are generally stored as binary alignment mapping (BAM) files. The SAM files were then sorted and 
converted into BAM file using samtools sort. The BAM files store the same information as the SAM 
files in a smaller size due to compression and thus are more suitable for memory-efficient storage. The 
resulting BAMs were later used for further downstream analysis. All the runs are performed in parallel 
using shells scripts from 82 samples on UNIX platform. 
2.3.3  Transcript assembly and read quantification 
The transcript assembly and read quantification were performed using, StringTie, a fast-de-novo 
assembler. We used StringTie with default parameters, along with the -e flag. The -e flag was used to 
generate files which can be used to estimate the raw read counts. We performed StringTie runs input 
BAM file, GTF reference genome (-G, GENCODE annotation V19) along with other default parameters. 
Transcript abundance is first computed and from which the gene expression is inferred. StringTie 
reported read abundances in FPKM units. FPKM is commonly used for paired-end RNA-seq. In paired-
end RNA-seq two reads can correspond to a single fragment. The relative abundances of transcripts are 
described in terms of the expected biological objects (fragments) observed from an RNA-Seq 
experiment. As StringTie assembles the transcripts and estimates its expression level simultaneously, the 
output from StringTie was many files: one contains the assembled transcript and the other contains the 




which in gtf format. 
The assembled transcripts are quantified using the PreDE python script provided by the StringTie 
developers. Using the PreDE script we obtained the gene expression counts for each gene. The script 
summarized the FPKM values from all samples and converted it into raw read counts. In order to make 
a matrix of read counts of all samples, we parsed all the sample files using os.path.join module and then 
concatenated all the files based on their gene identifiers (Geneid) and expression values as a count matrix 
using pandas concat function. 
This count matrix was later used for principal component analysis and differential expression analysis 
using the R Bioconductor package. The R Bioconductor packages for differential expression analysis 
takes in raw read count matrix mapped to a particular genome feature (example, gene) as their input. The 
raw read matrix was of gene identifiers (gene ID) as rows and their expression value of each sample as 
columns. 
2.4  Reference genome and annotation files used 
The lncRNAs were annotated using the GENCODE lncRNA annotation (V19), a manually curated and 
evidence-based lncRNA annotation consists of 13,860 lncRNA genes and its 23,898 transcripts. The GTF 
file was converted into the text file with gene identifiers, gene symbols, and gene biotype and their 
chromosomal position, extracted from GTF file using awk shell script. We then used a python script 
(pandas merge) to merge the “Geneid” between our count matrix and text file extracted from reference 
GTF file. The lncRNAs genes defined in GENCODE v19 version consists of 5276 antisenses with 9710 
transcripts, 21 3prime overlapping non-coding RNA with 25 transcripts, 3055 lincRNAs with 3116 
transcripts, 742 sense intronic with 802 transcripts, 202 sense overlapping genes with 330 transcripts and 
515 processed transcript genes with 28082 transcripts, which made a total of 13,3860 lncRNAs. The 
same procedure was followed for identifying PC genes as well. The Gencode v19 version consists of 
20,356 PC genes with 81,814 transcripts. 
2.5  Unsupervised clustering using Principal Component Analysis (PCA) 
We used a dimensionality reduction method PCA for unsupervised clustering on the expression and 
DNA-methylation of lncRNAs across all samples. We performed the principal component analysis on all 
13,365 lncRNAs from all BCP-ALL RNA-seq samples. The PCA was performed using the R function 
prcomp on the FPKM values of lncRNAs. The R function prcomp uses the spectral decomposition 




constructed using the python library matlabplotlib on the most variable principle components. 
2.6  Identification of differentially expressed lncRNAs 
The subtype-specific lncRNAs were identified from the whole cohort of 82 samples from 20 adult and 
25 pediatric patients from ID and REL stages. We started off by analyzing the differential expression 
(DE) lncRNAs on factors including, age (Pediatric versus adult patients) and disease progression 
(diagnosis versus relapse) which did not result in distinct DE lncRNAs expression profile. 
We next aimed to identify the DE lncRNAs or subtype-specific lncRNAs for the three subtypes, Ph-like, 
DUX4, and NH-HeH. For all samples, we applied a filter by removing the genes which are not expressed 
in at least 25% of samples to eliminate unreliability in the measurements of genes (Figure 2.7.1). 
In the experimental design, we noticed that we have biologically dependent samples, for example, we 
had paired ID and REL samples from 45 patients, with some exceptions. Eight of 45 patients had no 
matching ID or REL. Moreover, the patient and subtypes were confounded. The R Bioconductor package 
LIMMA Voom can model the multi-stage scenario with its in-build duplicate correlation feature. Thus, 
we took advantage of it and used LIMMA Voom for the DE expression analysis. 
We fed the raw read matrix as input to LIMMA Voom, which is then normalized using log2-counts-per-
million (logCPM) approach. The LIMMA Voom uses calcNormFactors function for normalization. In the 
differential expression analysis and all related analysis, the raw count is rarely considered, mainly due to 
the varying library size, the libraries are sequenced at a greater depth and will result in higher counts. 
Thus, it is the norm to convert the raw counts into a scale that accounts for such library size differences. 
Some of the popular conversions are counts per million (CPM), log-CPM, reads per kilobase of transcript 
per million (RPKM), FPKM and TPM. LIMMA Voom started with the normalization of raw expression 
counts. 
Normalization can significantly improve the quality of analysis and will lessen the bias across samples. 
Ideally, all samples are assumed to have similar distribution range of expression values. Normalization 
is used to ensure that the range of expression distributions of all sample are similar across the experiment. 
The normalization method LIMMA Voom employs is a trimmed mean of M-value (TMM) (Robinson & 
Oshlack, 2010). In LIMMA Voom, the normalization is performed by the calcNormFactors function. We 
used boxplots to visualize the difference of expression distribution of all samples’ unnormalized count 
matrix (Figure 2.6.1 A) versus normalized count matrix (Figure 2.6.1 B).  For our samples the effect of 




close to 1 (Figure 2.6.1 B). Normalization helps to make intuitive sense out of the data. Also, scaling 
enabled our data to be incorporated into the LIMMA method to conduct the DE analysis. The boxplots 
are constructed using R graphical package boxplot. 
 
2.6.1  Analysis matrix and contrasts 
After normalizing the samples, the next step was to develop a design matrix. We studied three different 
subtypes of BCP-ALL: DUX4 (n = 23), Ph-like (n = 21), and NH-NeH (n = 16). The DE analyses on 
these three subtypes were performed separately where each subtype was compared to the all other 
samples (Figure 3.7.10). For example, when the DUX4 subtype is used for DE analysis, treatment group 
was formed by all DUX4 samples (n = 23) and the rest of the cohort (n = 59) as a control group. The 
same design was followed for the other two subtypes. For dysregulated relapse -specific lncRNAs, we 
used REL samples as the treatment group and ID samples as the control group within each subtype. 
Firstly, we started with setting up a design matrix using the model. The design matrix was formed by 
providing the information about the samples, including condition, control, and time (ID or REL). 
Contrasts for pairwise comparisons between paired samples can be set up in LIMMA using the make 
contrasts function. In our study design, we needed to include the following two complexities into the 
contrasts in order to avoid the bias including, biological dependence and time-dependence. We, therefore, 
needed to account for biologically dependent samples using the duplicateCorrelation function by 
 
Figure 2.6.1: Box Plots of log-CPM values showing expression distributions for unnormalized data on the 82 
BCP-ALL samples. 
A. The unnormalized 82 BCP-ALL samples. B. The boxplot represents same dataset after TMM-normalization, 




specifying patients as block argument. The duplicateCorrelation takes the expression matrix, the design 
variable, and specified block argument, that is, in our case-patient information. We then included time 
information also in contrast. 
2.6.2  Examine DE genes from LIMMA 
The differential expression analysis was done on two models. Firstly, between each subtype versus others 
(for subtype-specific lncRNAs) and secondly, within each subtype we looked for DE lncRNAs between 
ID and REL samples (for relapse-specific lncRNAs). The output from LIMMA Voom consisted of genes 
and its corresponding P-values, which was determined using moderated t-statistic test, false discovery 
(FDR) value determined using Benjamini and Hochberg's method and log fold change of each gene. 
 
Next, the significantly differentially expressed genes were classified based on the following cutoffs: P-
value <=0.01 and fold change ⇔+-1.5. That is, the genes above the fold change of +1.5 are up-regulated 
and below -1.5 are down-regulated. 
In order to filter the lncRNAs from the output file using the above-mentioned cut-offs we wrote a python 
script using pandas.DataFrame.query function and for the annotation between the output matrix and 
GENCODE file we used pandas merge function. In order to find overlaps between subtype-specific 
lncRNAs, we used Venn3 package from matplotlib-venn. The significant up and down-regulated 
lncRNAs are hereafter refereed to as subtype-specific and relapse-specific lncRNAs and these were then 
 
Figure 2.6.2: The DE subtype-specific lncRNAs identification workflow 




used for the further downstream analysis. 
2.7  Validation of the subtype-specific lncRNAs 
An independent validation cohort of predefined BCP-ALL samples was used to validate our subtype-
specific lncRNAs. The independent validation cohort consisted of 47 patients from the ID stage (age: 
median 32 years, range 1-80 years) (136). The samples were previously defined based on their genomic 
and molecular profile as DUX4 (n=17), Ph-like (n=27), and NH-HeH (n=3). We used our 1534 subtype-
specific lncRNAs from our discovery cohort and performed an unsupervised clustering using 
complexheatmap R package using correlation-based clustering on lncRNAs expression and samples 
using the Spearman method. The column barplot represents the subtypes within the cohort, which was 
defined using HeatmapAnnotation function with complexheatmap R package. 
2.8  Hierarchical cluster analysis 
The graphical representation of high dimensional data sets is key for straightforward explanatory analysis 
and hypothesis generation. With genomics dataset, the most commonly used methods are heatmaps 
combined with hierarchical clustering. The hierarchical clustering builds a dendrogram (a tree-like 
structure) where the leaves are the samples or variables. The algorithm consecutively pairs together the 
samples showing the highest degree of similarity. These samples are then collapsed into a cluster and 
treated as a single object in all the following steps. 
For the hierarchical cluster analysis and heatmap illustration, we used the subtype-specific and relapse-
specific lncRNAs (Fold change <> +-1.5, P-value <= 0.01). The LIMMA Voom normalized expression of 
those both sets of lncRNAs were then transformed into row-based Z-scores. 
𝑍 − 𝑠𝑐𝑜𝑟𝑒 = 𝑥 − 𝜇 ÷ 𝜎 
Where x is the normalized gene expression count, μ is the mean of the gene expression across the samples, 
and σ is the standard deviation of the gene expression. Hierarchical clustering (HC) was done on DE 
lncRNAs, the method is based on calculating the distance and correlation between each samples 
(columns) the genes (rows). The most correlated genes and samples from clusters visible in the heatmap. 
The distance-based correlation was performed using the Spearman method. We used the “complete” 
method to calculate the distances between clusters; this method uses the farthest distance between objects 
from the first cluster and objects from the second cluster. For the lncRNAs or rows we implemented km 
=3, the K-mean clustering split the rows for 3 clusters to define row-clusters or lncRNAs clusters. We 




clusters. The same approach was used for all subtypes and DNA methylation hierarchical clustering. 
Heatmaps provide large-scale qualitative views of the transcriptomic landscape by representing the 
quantitative differences in gene expression levels measured from RNA-seq or microarray technologies. 
We used R Bioconductor package ComplexHeatmap to plots our DE heatmaps and DNA methylation 
results (Zuguang Gu, Eils, & Schlesner, 2016). 
2.9  Functional analysis by the guilt-by-association approach 
LncRNAs can also positively or negatively regulate the expression of these cis genes located nearby, 
overlapping, or within protein-coding genes. We next aimed to determine functions of lncRNAs based 
their positive correlations with cis and trans lncRNAs. In our study, we used the “guilt-by-association” 
approach by establishing the correlations between the expression of lncRNA genes and their cis and trans 
PC genes. This method is most used and validated method regarding finding functions of lncRNAs. We  
 
located the cis and trans protein-coding genes for our subtype-specific lncRNAs, a set of 1564 lncRNAs 
from the three subtypes using the GREAT tool (McLean et al., 2010). GREAT is a graphical user interface 
(GUI), which accepts a list of background genes and test genes (Figure 2.10.1). Both the background 
 
Figure 2.9.1: The work-flow used for functional predictions 
Guilt-by-association approach used in functional predictions of differentially expressed lncRNAs from BCP-ALL 
subtypes. The circle indicates the lncRNAs and the yellow triangles are neighboring protein-coding genes. The purple 
triangles indicate trans protein coding genes which located in genomic location >100 kb distance or in another 
chromosome. Both cis and trans protein coding genes were located using GREAT interface. Then in the next step we 
calculated pairwise correlation using Pearson's correlation method, and the most significant genes were then used for 




genes (~20,000 PC genes) and all subtype-specific (test genes) (n = 1534) lncRNAs were fed into the 
GREAT database in Browser Extensible Data (BED) file format. The input BED file contained the 
information of chromosomal position (chromosome, start, and end) then the gene symbol (Ensemble 
gene symbol) of lncRNAs and protein-coding (PC) genes. This BED file was constructed from the 
filtered subtype-specific lncRNAs text file using sed and awk one-liners on the command line. In the 
GREAT tool, we checked “two nearest gene” option with the “Associating genomic regions with genes 
session”. Where we defined 100 kilobase (kb) for the cis PC genes, which are located within a proximity 
of from the lncRNAs transcription start site (TSS) site. In order to determine the trans PC, we defined 
greater >100 kb from the TSS of the lncRNAs in the checkbox. And then we submitted our query to the 
GREAT algorithm. The GREAT run resulted in a list of cis and trans located PC to their corresponding 
lncRNAs as text files with their genomic distance. Firstly, we used regular expression [regex = 
r'(?P<PC>\w+.*).*\((?P<Strand>[+-])(?P<Distance>.*)\)'] and extracted all lncRNAs and their 
corresponding cis and trans PC genes using python lambda extract and groupby functions into a tab 
separated file. Once we had all the list of cis and trans PC genes as tab separated file, we again filtered 
out the cis PC genes from trans list using query function from python panda’s library. 
2.9.1  Co-expression analysis between subtype-specific and relapse-specific lncRNAs and their 
cis and trans located PC genes 
Computing Pearson correlation quantifies correlations between genes. In order to test the significance of 
correlation we used 2-tailed test. The Pearson correlation analysis was performed using python's 
scipy.stats.pearsonr mathematical algorithm from python. We calculated a pairwise correlation on 
subtype-specific lncRNAs to their cis and trans protein-coding genes. For instance, for each subtype, we 
computed a pairwise correlation matrix between all DE lncRNA and between their cis and trans coding 
gene to produce two matrices of lncRNAs × cis protein coding. We obtained both positively and 
negatively correlated cis and trans protein-coding genes for each DE lncRNAs. We considered only 
positive correlations to characterize the lncRNAs of interest in our study. The significantly correlated 
protein-coding genes were ranked for each lncRNA by the correlation coefficient (Pearson's 
correlation >= 0.55, P-value <= 0.05) as co-expressed genes or positively correlated genes for each 
subtype. This filtering was done python script written using query function. The resulted gene list enabled 
us to generate hypotheses regarding the function of a given lncRNA based on how they are enriched in 
pathways. The same procedure was followed for functional characterization of dysregulated lncRNAs 




2.9.2  Functional enrichment of significantly correlating genes using GeneSCF tool 
We used Gene Set Clustering based on Functional annotation (Subhash & Kanduri, 2016) (GeneSCF 
version 1.0) for our functional enrichment analysis for the subtype-specific DE lncRNAs and relapse-
specific DE lncRNAs. The GeneSCF is a command line tool. We had a plain text file with all our PC 
gene symbols which were significantly correlated with the subtype-specific lncRNAs. gtype=sym). The 
functional enrichment analysis was performed by the following parameters: defined the input text file 
with significantly co-expressed PC genes using -i=input plain text file, defined the input gene symbol 
using -t=sym and source database using -db=KEGG. After that, the tool outputs the gene hits along with 
the corresponding functional pathways as a table. The significant pathways were filtered based on P-
value <=0.05, the same procedure is followed for all subtype in order to maintain consistency in the 
analysis process. We used awk to filter out the functional pathways falling within the cut-off. 
2.10  DNA methylation analysis 
We next, sought to comprehensively define the DNA methylation profile of BCP-ALL subtypes in patient 
samples. In order to define the DNA methylation profile, we isolated genomic DNA (0.5 μg) from BCP-
ALL (n = 82) samples at ID and REL conditions from the same 45 patients. These samples were then 
hybridized onto an Illumina 450k methylation array. The beta values representing the signal density of 
CpG sites were obtained from DNA methylation array for all samples. 
2.10.1  DNA methylation dataset preparation and normalization 
A beta value refers to the measure of the degree of methylation at each measured locus. Beta values are 
powerful for large-scale studies as it can be transmitted and compared across samples. The obtained beta 
(β-values) values from each CpG sites, were then normalized using SWAN method. Normalization is 
used to remove the technical variation between measurements, by maintaining the true biological 
difference between samples and probes. SWAN normalization was used as this method improves the 
correlation between biological or technical replicate, while the increasing the detection of some 
significantly differentially methylated probes. In addition to that, we can use them with any R package 
further for detection of differentially methylated probes. SWAN normalization method has two parts; the 
first part determines the average quantile distribution using a subset of probes defined to be biologically 
similar based on CpG content. The second step is to then adjust the intensities of the remaining probes, 
mainly from Infinium II than I, by insertion onto the distribution of the subset probes. This is done for 
each probe type separately using linear insertion between the subset probes to define the new intensities. 




still vastly different from the distribution of Infinium II probes (Maksimovic, Gordon, & Oshlack, 2012). 
The obtained SWAN normalized value was saved in a matrix for further bioinformatics analysis. The 
data matrix consisted of CpG's identifications as rows and beta values for all 82 BCP-ALL as columns. 
2.10.2  DNA methylation profile of lncRNAs across samples 
The positions of each CpG's from the SWAN normalized data matrix was identified using R package 
IlluminaHumanMethylation450kanno.ilmn12.hg19 using “@data$Locations. Which resulted in the 
genomic position information, including, chromosomal positions, and gene symbols for each CpG sites 
for our input matrix. Annotation of the CpG signals represented in SWAN normalized beta values 
obtained from the array resulted in the identification of 60,021 CpG probes corresponding to 7190 
lncRNA genes and 120,000 CpG probes corresponding to around 15,000 PC genes. DNA methylation 
analysis started by looking into the level of DNA methylation profile between lncRNAs and PC genes 
across 82 BCP-ALL samples. The density plots were plotted using python. plot function, on M-values 
(β-logit2 transformed). The logit transformation was performed by python scipy.special.logit algorithm. 
 
2.10.3  PCA on the lncRNAs DNA methylation profile 
We then used the same matrix to see how the samples are clustered based on their DNA methylation 
profile using PCA analysis using the R function prcomp on the SWAN normalized values for lncRNAs 
associated CpG sites (n = 60,021). The 3D PCA plots are constructed using the python library 
 
Figure 2.10.1: The DNA methylation analysis work-flow fro defining the differentially methylated subtype-
specific lncRNAs 





2.10.4  Differential methylation analysis 
We performed differential methylation analysis using the R Bioconductor package, Bumphunter using 
the most variant quartile of CpG probes, searches for differentially methylated regions in an annotation-
unbiased manner (Jaffe et al., 2012). We separated the ID and REL samples for each DUX4, Ph-like, and 
NH-HeH subtype in order to account for the biological replicate dependency. To determine differentially 
methylated regions (DMRs), we used R to apply 1000 permutations with the Bumphunter algorithm and 
considered significant regions of P-value < 0.05, CpGs differently methylated. Each subtype was 
compared with other samples for differential methylation analysis (Figure 2.12.1). In order to define 
statistically significant hyper-methylated genes and hypo-methylated genes we then used previously 
defined criteria by Bumphunter package [http://genomicsclass.github.io/book/pages/epiviz.html].The 
significant hyper-methylated genes were defined if the differential methylation value > 0.2 and P-value 
<= 0.05 and the significant hypo-methylated genes were defined if the differential methylation value is 
< 0 and P-value <= 0.05. The hyper-methylated genes are the ones who showed an elevated methylation 
rate compared to other samples, and the hypo-methylated genes are the ones which a decreased 
methylation rate compared to the others. 
2.10.5  Association of subtype-specific DM with different genomic regions and finding subtype-
specific DM lncRNAs 
We associated the differentially methylated regions from three BCP-ALL subtypes using hypergeometric 
optimization of motif enrichment (HOMER) suite of tools 
[http://homer.ucsd.edu/homer/ngs/customGenomes/index.html]. We performed annotation of DM sites 
using 'annotationPeaks.pl.' tool using the encode.v19.annotation.gtf reference file. In order to get all 
information about the genomic regions including, the gene symbol, gene type, distance from the 
promoter-TSS region, and genomic regions (intron, exon, promoter-TSS, Transcription Termination site, 
etc.), gene type, and the distance from the promoter-TSS of each gene, we used the -gene parameter. The 
input for 'annotationPeaks.pl' tool was BED files defining the chromosomal potions of each significant 
DM regions obtained from Bumphunter and the reference file (encode.v19.annotation.gtf ) which was 
converted into a tab-delimited gene data file using awk command line script. With these inputs 
'annotatePeaks.pl’ provided us with all the essential information about the genomic region corresponding 
to each CpG sites for our DM genes. Using this information, we identified lncRNAs from our DM list 




The genomic regions were defined as promoter-TSS and gene body. The gene body was defined if the 
CpGs are annotated in exonic, intronic or transcription termination site (TTS). We used the list of all 
lncRNAs biotype to filter the lncRNAs from the output file. The awk and grep commands were used to 
filter out the lncRNAs. The promoter-TSS is assigned based on the genomic window of -2000 base pairs 
downstream and 2000 base pair upstream to the TSS region. The regions mapped to lncRNAs were then 
used for analysis. These filtered DM lncRNAs were further used for remaining comparison analysis. 
2.10.6  Correlation analysis between DM of lncRNAs and their expression levels 
We used the results from Bumphunter and LIMMA Voom for DM and DE subtype-specific lncRNAs 
signatures to compare the DNA-methylation and expression. First, we overlapped the promoter-TSS 
methylated lncRNAs and the DE lncRNAs. Out of these, we used the overlapped promoter-TSS 
methylated lncRNAs for comparative analysis. Next, the reverse correlation was determined between 
DNA-methylation and expression level by correlating the DNA methylation values (β-logit2 
transformed) with the log2 transformed FPKM values of each lncRNAs. The correlation was determined 
by the previously mentioned Pearson correlation method using python scipy. stats. Pearson library. The 







Chapter 3. Results 
3.1  The expression and DNA methylation profile of lncRNAs 
To systematically identify subtype-specific lncRNAs from three BCP-ALL subtypes we analyzed 
transcriptome and DNA methylation profiles from paired ID and REL samples of 25 pediatric and 20 
adult BCP-ALL patients lacking known chromosomal translocations like BCR-ABL. Based on 
expression signatures of PC genes, fusion genes, mutations, deletions and DNA methylation profile 
detected by RNA expression and DNA methylation profiles, the samples (n = 82) were classified into 
different molecular subtypes, namely, DUX4 (n = 23), Ph-like (n = 21), NH-HeH (n = 16), and low-
hypodiploid (LH; n = 6). The DNA methylation data were extracted from the same samples using DNA 
methylation array platform, which accounted for 60,022 CpG's located annotated as lncRNAs (n = 7160) 
in the genome. 
 
We started by comparing the distributions of expression and DNA methylation profile between lncRNAs 
and protein-coding (PC) across all BCP-ALL. Consistent with the previous reports (Casero et al., 2015), 
we observed the lncRNAs (n = 13460) were less abundantly expressed than the PC genes (n = 20,135) 
(Figure 3.1.1 A). Whereas, when the DNA methylation profile of CpG sites (n = 60,021) associated with 
7,160 lncRNAs was compared with CpG sites associated with PC genes (n = 120,000) across all BCP-
 
Figure 3.1.1: The expression and DNA methylation profile of lncRNAs and protein coding genes across all 
samples. 
A. The level of distribution of expression between 13460 lncRNAs and 20,135 PC genes across 82 BCP-ALL samples. 
B. The level of distribution of DNA methylation rate between 60,022 CpGs probes associated with lncRNAs region and 
120,000 CpGs probes associated with PC genes across 82 BCP-ALL samples. The x-axis represents the DNA 




ALL samples (Figure 3.1.1 B), we identified a similar DNA methylation profile between lncRNAs and 
PC genes. 
3.2  Unsupervised hierarchical clustering of lncRNAs expression identified robust 
clusters of BCP-ALL subtypes 
In order to identify the ability of lncRNAs to stratify BCP-ALL samples as the PC genes, we performed 
unsupervised clustering using principal component analysis (PCA) on the normalized (FPKM) 
expression values of 13,860 GENCODE lncRNAs. The PCA analysis revealed three distinct robust 
clusters of BCP-ALL subtypes, DUX4, Ph-like and NH-HeH (Figure 3.2.1 A). 
 
This observation was in concordance with the predefined molecular classification of BCP-ALL 
subtypes. In order to validate the ability of lncRNAs in distinguishing subtypes, we extended the 
same PCA approach on the lncRNAs expression (13860 lncRNAs FPKM value) on an independent 
cohort, that we termed as “independent validation cohort”. The samples within the independent validation 
cohort were predefined based on their molecular profile into DUX4 (n = 17), Ph-like (n= 27) and NH-
HeH (n = 3) subtypes. We identified a similar observation as with our discovery cohort (Figure 3.2.1 B) 
 
Figure 3.2.1: Unsupervised clustering of lncRNAs expression in BCP-ALL samples on the discovery and 
validation cohort. 
A. The unsupervised clustering (PCA) on the lncRNAs expression of BCP-ALL samples of the discovery cohort (n=82), 
representing distinct clusters of DUX4, Ph-like and Nh-HeH subtypes. The PCA plot constructed from expression 
FPKM values of lncRNAs from 82 BCP-ALL samples obtained from RNA-Seq from the original discovery cohort. B. 
The unsupervised clustering on the independent validation cohort of 47 BCP-ALL samples, representing the distinct 
clusters of DUX4, Ph-like and Nh-HeH subtypes. The PCA plot constructed from expression FPKM values of lncRNAs 
from 47 BCP-ALL samples obtained from RNA-Seq from the validation cohort. Each point represents a BCP-ALL 





in the independent cohort. We, therefore, sought to identify lncRNAs signatures which are differentially 
expressed within these three subtypes in our discovery cohort. 
3.3  Differentially expressed lncRNAs across multiple BCP-ALL subtypes 
To identify the subtype-specific differentially expressed (DE) lncRNAs signatures in the BCP-ALL 
samples we analyzed each subtype (DUX4, Ph-like, and NH-HeH) versus the rest of the cohort. A total 
of 1564 (P-value <= 0.01 and Fold change <=> -+1.5) subtype-specific lncRNAs were identified as DE 
from the three subtypes (Figure 3.3.1 A). By comparing subtype-specific DE lncRNAs (n = 1564) from 
these three subtypes, we found 59% (n = 930) of lncRNAs are specific to each subtype, the remaining 
lncRNAs were shared in at least two subtypes (Figure 3.3.1 B). We identified 24 lncRNAs whose 
expression was significantly altered in DUX4, Ph-like and NH-HeH BCP-ALL subtypes (Figure 3.3.1 
B). 
The large size of the DUX4 subtype signature distinguishes the DUX4 subtype as particularly perturbed 
at the level of lncRNAs gene expression. The subtype-specific DE lncRNAs based hierarchical clustering 
revealed distinct and robust clusters for each BCP-ALL subtype (Figure 3.1.1 A-C), defining lncRNAs 
driven molecular signatures in BCP-ALL subtypes. 
 
 
Figure 3.3.1: Number of subtype-specific lncRNAs 
A. The barplots represents the number of significantly up and down regulated subtype-specific lncRNAs. B. The Venn 




We next compared our subtype-specific DE lncRNAs signature with different cancer types from a 
comprehensive genomic characterization of lncRNAs across cancers (CGC) (X. Yan et al., 2015). We 
found about 59% (n = 712, Figure 3.3.1 D; Hypergeometric test P-value = 9.2e-29) of our subtype-
specific lncRNAs were more specific to the investigated three BCP-ALL subtypes (Figure 3.1.13 A-C). 
Out of the overlapped DE lncRNAs (n = 523), 23 (Appendix 1) lncRNAs were previously defined as 
cancer-related lncRNAs from the lnc2cancer database (Ning et al., 2018). For example, oncogenic 
lncRNAs PVT1 (Tseng & Bagchi, 2015) and GAS5 (Mazar et al., 2016) are differentially up-regulated in 
the DUX4 subgroup, and CRNDE (Huan, Xing, Lin, Xui, & Qin, 2017) is DE is down-regulated in the 
Ph-like subtype. Together, this demonstrates that the dysregulated expression of lncRNAs in for BCP-
ALL subtypes. 
 
3.4  Further validation of the subtype-specific lncRNAs with an independent BCP-
 
Figure 3.3.2: BCP-ALL subtype-specific differentially expressed lncRNAs. 
A-C. The hierarchical clustering representing lncRNAs clustering and expression differences of the compared subtypes DUX4, Ph-like and NH-HeH; 
corresponding to 736, 383, and 445 subtype-specific DE lncRNAs in DUX4, Ph-like and NH-HeH subtypes, respectively. In the DUX4 subtype, 100% of 
samples clustered together based on the DE lncRNAs signature. The hierarchical clustering of the subtype-specific DE lncRNAs revealed that 90% (19 out 
of 21 samples) of Ph-like samples clustered within the predefined Ph-like subtype. For the NH-HeH subtype, 69% (11 out of 16 samples) of samples correlated 
and clustered together using the respective DE lncRNA signature. The BCP-ALL samples box representing the number of samples within each subtype and 
versus (vs) the other samples used as a control group in DE analysis. D The overlap between DE subtype specific lncRNAs from three subtypes versus a 





We observed distinct clusters for three subtypes based on unsupervised HC on the 1235 subtype-specific 
lncRNAs (299 out of 1534 is present at least in one of the three subtypes) (Figure 3.1.14 A) in the 
discovery cohort (n = 82). To confirm subtype-specificity of these dysregulated lncRNAs, we made use 
of the previously defined independent validation cohort. Unsupervised hierarchical clustering on the 
expression of 1235 subtype-specific lncRNAs on the independent validation cohort identified three 
robust clusters confirming the (Figure 3.1.14 B) subtype-specificity of our 1235 subtype-specific 
lncRNAs. Taken together, the results with independent validation cohort demonstrated better and 




Figure 3.4.1: Validation of subtype-specific lncRNAs on independent validation cohort. 
A. Heatmap illustrates hierarchical clustering (HC) DE subtype-specific lncRNAs (absolute Fold change >= +- 1.5, P-value <= 0.01) signature based on z-
score transformed LIMMA normalized expression values on 1235 subtype-specific lncRNAs from DUX4 (n = 450), Ph-like (n = 193), and NH-HeH (n = 
287) subtypes. The spearman correlation-based clustering is done on the lncRNAs. B. The heatmap represents the expression pattern of 1235 subtype-specific 




3.4.1  Identification of subtype-specific lncRNAs functions 
We next asked whether these 1235 subtype-specific lncRNAs might be globally related to the alteration 
of different biological functions and molecular pathways. Since lncRNAs exert their actions by regulating 
the PC genes in cis and trans regions, we performed functional enrichment analysis using the previously 
defined guilt-by-association approach on both cis and trans PC genes (Table 4.4.1). This enabled us to 
generate hypotheses regarding the function(s) of a given subtype-specific lncRNAs. Functional 
enrichment analysis was performed based on the correlation between neighboring (cis) and distally 
(trans) located protein-coding (PC) genes (within ± 100 kb cis and >± 100 kb window for trans) of the 
subtype-specific lncRNAs from the subtypes. The significantly co-expressed cis and trans PC genes 
based on their positive correlation rate (Pearson correlation >= 0.55 and two-tailed P-value <= 0.05) were 
then used for functional enrichment analysis. Consistent with other reports (Casero et al., 2015), we 
observed the higher number of positive correlations (Pearson correlation rate >= 0.55 and two tail P-
value <= 0.05) than the negative correlated cis and trans genes. The table represents the number of 
positive correlated PC genes (Table 3.4.5). 
Table 3.4.5: Number of BCP-ALL subtype specific co-expressed lncRNAs with it's cis and trans PC genes. 
Subtypes 
Cis PC genes 
(n = 929) 
LncRNAs co-
expressed with cis PC 
genes 
(n = 621) 
Trans PC 
genes 
(n = 753) 
LncRNAs co-expressed with 
trans PC genes (n = 552) 
DUX4 669 451 (736) 492 379 (736) 
Ph-like 260 170 (383) 261 173 (383) 
Table 3.4.5: The table represents the number of subtype-specific lncRNAs with cis (<100 Kb proximity) and trans 
(>100 Kb) protein-coding genes and the number of their co-expressions. The numbers shown within the bracket is the 
otal number of DE lncRNAs corresponding to the respective subtypes. The percentage of cis co-expression is, 68%, 
44.3%, in the DUX4 and Ph-like subtypes respectively. The percentage of trans-co-expression is, 51.5%, 45.2%, in the 






Out of these cis (n = 451) and trans (n = 379) co-expressed lncRNAs from DUX4 subtype, we identified 
58 and 127 lncRNAs significantly co-expressed with 45 cis and 49 trans PC respectively. In Ph-like 
subtype, we identified 24 (Appendix C) and 20 subtype-specific lncRNAs co-expressed with 25 cis and 
37 trans located PC genes respectively. These genes were enriched in signaling pathways, including, 
Janus kinase and Signal Transducer and Activator of Transcription (JAK-STAT), cytokine-cytokine 
kinase receptor, and phosphoinositide 3-kinase (P13K-Akt) signaling pathways (Figure 3.4.3, Figure 
3.4.4 C) based on the cis PC gene co-expression-based analysis. 
Figure 3.4.2: The molecular pathways of lncRNAs involved in the DUX4 subtype. 
The plot depicts the molecular pathway analysis from the functional enrichment analysis for nearby (<= 100 kb proximity) cis protein-
coding genes correlated (Pearson correlation coefficient >= 0.55 and 2-tailed P-value <= 0.05) with DE lncRNAs in the DUX4 subtype. 
The barplot in the right-hand side represents the number of genes involved in each pathway. The KEGG pathways or biological functions 
presented in the plot are with P-value <= 0.05 and > 2 genes within each pathway. The hypergeometric P-values are obtained from 
GeneSCF tool for the pathways. 
 
Figure 3.4.3: The molecular pathways of lncRNAs involved in the Ph-like subtype. 
A. The plot depicts the molecular pathway analysis from the functional enrichment analysis for nearby (<= 100 kb proximity) 
cis protein-coding genes correlated (Pearson correlation coefficient >= 0.55 and 2-tailed P-value <= 0.05) with DE lncRNAs 
in the Ph-like subtype. The barplot on the right-hand side represents the number of genes involved in each pathway. The 
KEGG pathways or biological functions presented in the plot are with P-value <= 0.05 and > 2 genes within each pathway. 





These 45 cis and 49 trans located PC genes were enriched in pathways involved in proliferation, 
apoptosis, and differentiation in leukemia. For example, the DUX4 subtype we identified signaling 
pathways including, Transforming growth factor Beta (TGF-Beta), P53, Endocytosis, and hippo 
signaling pathway, and Proteoglycans in cancer pathways (Figure 3.4.2, Figure 3.4.4 A-B). 
  
 
Figure 3.4.4: Comparison of molecular pathways from cis and trans based analysis on subtype-specific DE 
lncRNAs. 
 A. Molecular pathway analysis from functional enrichment analysis for distant (>100 kb) trans protein-coding genes 
correlated (Pearson correlation >0.55 and P-value <=0.05) with DE lncRNAs in the DUX4 subtype. B. The molecular 
pathways overlapped between cis (<100 kb proximity) and trans (>100 kb) based functional enrichment analysis in the DUX4 
subtype. C. Molecular pathway analysis from functional enrichment analysis for distant (>100 kb) trans protein-coding genes 




3.4.2  The lncRNAs based and mRNAs based functional enrichment analysis showed the same 
pathways in the subtypes 
In order to validate our predictions, we then linked the functions predicted for subtype-specific lncRNAs 
to those predicted for respective subtype-specific mRNAs. The comparisons were done between the DE 
PC based and DE lncRNAs based functional pathways from DUX4 and Ph-like subtypes. Interestingly, 
we observed all signaling activated in DUX4 DE PC based analysis are activated or inhibited in the DE 
DUX4 specific lncRNAs based analysis (Figure 3.4.5 A). Whereas, in the Ph-like subtype, we identified 
60% (9 out of 15 pathways) overlap between the two sets of predicted functions (Figure 3.4.5 B). For 
example, JAK-STAT, Cytokine-cytokine receptor and endocytosis pathways had overlapped between 
both analyses; yet, there were cases where subtype-specific lncRNAs appeared to be more strongly 
associated with a function or pathway than subtype-specific PC genes. The key signaling pathways 
mTOR and P13K-Akt signaling pathways were more exclusive for lncRNAs based analysis in the Ph-
like subtype. 
3.4.3 DUX4 Subtype-specific lncRNAs represented in functional pathways predictions 
One of the key functions of lncRNAs is its ability to regulate the expression of its neighboring protein-
coding genes in the genome. In order to investigate to what degree this general concept may be applied 
 
Figure 3.4.5: Subtype-specific lncRNAs and PC genes displayed enrichment of same pathways in DUX4 and Ph-like 
subtypes. 
A. The heatmap depicts the concordance between the protein-coding and lncRNAs based predictions for DUX4 subtypes. B. 
The heatmap depicts the overlapping pathways from both lncRNAs and protein-coding in the Ph-like subtype. The KEGG 
pathways or biological functions presented in the heatmaps and barplots show with P-value <= 0.05 and > 2 genes involved 
in each pathway. The hypergeometric P-values are obtained from GeneSCF for the pathways. CAMs: Cell adhesion molecules, 




to the BCP-ALL subtypes-specific lncRNAs, we looked into genes which are present in different 
predicted signaling pathways from each subtype. Firstly, we started with identifying PC genes involved 
in activated signaling pathways associated with cellular processes including proliferation, differentiation, 
migration and cell survival. Secondly, we looked for subtype-specific lncRNAs which are co-expressed 
and located at the same locus of these PC genes. 
Among the co-expressed DUX4 specific lncRNAs (Pearson correlation > 0.55 and P-value <= 0.05, 
Appendix B) with cis-PC genes we identified 58 lncRNAs are correlated with their cis-PC genes that are 
involved in key signaling pathways. Some of these cis-PC genes are oncogenes involved in leukemia 
progression. For example, TGFB2 gene, SMAD1 is and ITGA6. Among these, the TGFB2 gene is 
enriched in key signaling pathways, including, Hippo and TGF-Beta signaling pathway and endocytosis. 
The antisense lncRNA RP11-224O19.2 which is encoded at TGFB2 locus aligning at the 5’ end showed 
a strong significant co-expression (Pearson correlation = 0.96, P-value = 2.6e-45) with the TGFB2 
(Figure 3.4.6 A). Interestingly, both TGFB2 and its antisense lncRNA RP11-224O19.2 are significantly 
up-regulated in the DUX4 samples (Figure 3.4.6 B, Table 4.4.2). 
Figure 3.4.6: The subtype-specific lncRNA RP11-224O19.2 co-expressed with TGFB gene in DUX4 subtype 
 The lncRNA RP11-224O19.2 and its cis oncogene TGFB2 is significantly co-expressed. Antisense RP11-224O19.2 
and its cis oncogene TGFB2 are encoded in the same locus (left panel).  Antisense RP11-224O19.2 (absolute fold-
change = 2.786, P-value = 9.74E-08) and TGFB2 (absolute fold-change = 3.84, P-value = 2.74E-10) genes are 
significantly up-regulated in DUX4 samples (Right panel). 
 
The SMAD proteins are signal transducers and transcriptional modulators that mediate multiple signaling 
pathways. The SMAD protein mediates the signals of the bone morphogenetic proteins (BMPs), which 
are involved in a range of biological activities including cell growth, apoptosis, morphogenesis, 




SMAD1-AS2 positively correlated (Pearson correlation = 0.75; 2 tailed P-value = 2.9e-16) with its sense 
gene, SMAD1. Other example, ITGA6 gene is enriched in the PI3K-Akt signaling pathway, cell adhesions 
molecule and focal adhesion. The antisense lncRNAs AC093818.1 (Pearson correlation = 90; P-value = 
2.1e-30) and AC078883.3 (Pearson correlation = 0.68; P-value = 2.8e-12) are co-expressed with their 
sense PC gene, ITGA6. Interestingly, both ITGA6 (absolute Fold change = 9.5; FDR = 9.1e-10) and the 
novel lncRNAs were co-expressed and significantly up-regulated in the DUX4 samples. 
3.4.4  Ph-like Subtype-specific lncRNAs represented in functional pathways 
Dissecting the pathways appeared in the Ph-like DE lncRNAs based analysis, we identified 24 Ph-like 
specific lncRNAs co-expressed with CDK6 and IL2RA oncogenes. These oncogenes were enriched in 
pathways, including, PI3K-Akt and JAK-STAT signaling pathways, and Cytokine-cytokine receptor 
interaction and endocytosis pathways. Twenty-four (Appendix C) Ph-like lncRNAs are co-expressed 
with these oncogenes. In Ph-like subtype, CDK6 gene is enriched in the PIK3-Akt pathway in the Ph-
like subtype, a pathway which prevents apoptosis. The CDK6 is a gene which appears to be frequently 
up-regulated in the malignant hematopoiesis (Scheicher et al., 2015) with a critical role in AML and ALL 
driven by mixed lineage leukemia fusion proteins (Van Der Linden et al., 2014). We then looked for 
lncRNAs associated with the CDK6 protein and identified seven novel lncRNAs (Figure 3.4.7 A, Table 
3.4.6), including its antisense lncRNA, AC002454.1 (-42918 bp, Pearson correlation = 0.72, Figure 3.4.7 
B). The role of antisense lncRNA AC002454.1 had previously been reported, including the ability to 
regulate CDK6 by inducing the cell cycle disorder (Y. Wang, Li, Yang, Liu, & Wang, 2015). The 
association of CDK6 and AC002454.1 are referred to as “head-to-head” association, as the 5’ end, both 
genes are aligned. The antisense lncRNAs are widely reported to be linked with multiple functions such 
as they regulate protein-coding genes positively or negatively. 
 Table 3.4.6: Novel lncRNAs co-expressed with oncogene CDK6, TGFB2, and IL2RA 
Subtype-specific 
lncRNAs 
Pearson coefficient P-value Subtype Oncogene 
RP11-347C18.3 0.56 3.25E-008 
Ph-like CDK6 
RP11-461F16.3 0.62 5.21E-010 
RP11-96H19.1 0.62 3.89E-010 
RP11-228B15.4 0.64 7.68E-011 
MME-AS1 0.56 3.68E-008 
CTB-39G8.3 0.57 1.78E-008 




RP11-582J16.4 0.55 8.08E-008 
AC009970.1 0.64 6.23E-011 
RP11-229P13.20 0.66 1.44E-011 
LINC00114 0.57 3.06E-008 
CTB-118N6.3 0.61 9.70E-010 
SOCS2-AS1 0.62 4.94E-010 
CTD-2561B21.10 0.61 9.91E-010 
RP11-413E1.4 0.56 4.36E-008 
KB-1460A1.1 0.55 7.77E-008 
AC012309.5 0.59 4.10E-009 
RP11-37B2.1 0.59 4.76E-009 
ASB16-AS1 0.65 3.86E-011 
LINC00426 0.62 6.32E-010 
LINC01071 0.57 2.46E-008 
RP11-536K7.5 0.74 5.11E-15 IL2RA 
RP11-224O19.2 0.98 1.08E-061 
DUX4 TGFB2 
AC004837.5 0.83 6.11E-023 
RP11-251M1.1 0.79 7.39E-019 
CTD-2571L23.8 0.75 2.94E-016 
RP11-35O15.1 0.65 3.36E-011 
AC139100.3 0.58 1.00E-008 
RP11-158M2.3 0.58 1.50E-008 
RP11-672A2.5 0.56 4.68E-008 
CTD-2357A8.3 0.55 7.46E-008 
RP11-677M14.3 0.55 6.68E-008 
Table 3.4.6: The subtype-specific lncRNAs from DUX4, Ph-like associated with different signalling pathways. The 
table represents the lncRNAs and correlation rate between subtype-specific lncRNAs and PC genes enriched in various 
signaling pathways. 
Another example is the IL2RA, a gene which is involved in diverse biological functions such as cell 
proliferation, apoptosis, cell surface immune response, and MAPK cascade. Recently, IL2RA is found to 
be specifically up-regulated by pre-B cell receptor (pre-BCR) signaling during early B cell development 
(Sadras et al., 2017), and cells with activated tyrosine kinases by a manifold to pre-BCR signaling in 





coding genes; antisense RP11-536K7.5 is an example (Qureshi, Mattick, & Mehler, 2010). The antisense 
lncRNA RP11-536K7.5 and IL2RA gene are up-regulated (absolute fold change= 2.79; P-value = 3.07e-
08) in the Ph-like samples. Furthermore, the expression of RP11-536k7.5 shows a significant positive 
correlation (Pearson correlation = 0.73, P-value = 5e-14) with the expression of IL2RA gene (Figure 3.4.7 
C, Table 3.4.6). The antisense lncRNA AC002454.1, is up-regulated (absolute fold change = 1.7; P-value 
= 0.00015) in the Ph-like samples (Figure 3.4.7 right panel) compared to others. 
Table 3.4.7: Subtype-specific novel DE lncRNAs co-expressed with oncogenes, which are associated with 
important molecular pathways. 
 
 
Figure 3.4.7: The subtype-specific lncRNAs co-expressed with oncogenes involved in key signaling pathways in Ph-
like subtypes 
A Seven novel lncRNAs co-expressed with CDK6 gene. B. The expression of cis antisense lncRNA AC002454.1 significant 
co-expressed with its cis oncogene CDK6 in Ph-like subtype. Both CDK6 (Absolute fold change = 1.01, P-value = 0.0005) 
and antisense lncRNA AC002454.1 (Absolute fold change = 1.79, P-value = 0.00015) are up-regulated in Ph-like samples. 
C. Expression of antisense lncRNA RP11-536K7.5 showed significant co-expression with expression of its cis oncogene 
IL2RA. Both RP11-536K7.5 (absolute fold-change = 2.79, P-value = 3.07E-008) and IL2RA (absolute fold-change = 3.11, 
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Pathways in cancer transcriptional mis-regulation 
in cancer pathways 
Table 3.4.7: The table represents the novel subtype-specific DE lncRNAs co-expressed with its cis genes such as 
TGFB2, ITGA6, CD22, and RARA genes, which were enriched in vital molecular pathways in BCP-ALL. 
 
In summary, global co-expression analysis and gene-expression profiling suggest an important and 
previously unappreciated role for lncRNAs in BCP-ALL subtypes. Our analyses highlight important 
putative functions for subgroups of the subtype-specific lncRNA genes whose expression correlates 
tightly with leukemic oncogenes. 
3.5  Dysregulated relapse-specific lncRNAs as markers of BCP-ALL subtypes 
LncRNAs are reported to be linked with clinical outcome of several diseases (Herrera-Solorio et al., 
2017). Relapsed ALL, refers to the return of ALL in patients, and are mainly due to the poor outcome of 
conventional therapy. In order to investigate the relapse-specific DE lncRNAs, we performed differential 
expression analysis between initial diagnosis (ID) and relapse (REL) samples within each subtype. The 
DE analysis resulted in 941 dysregulated lncRNAs, in which, we identified 192 lncRNAs whose 
expression are up-regulated (Absolute fold change > +- 1.5; P-value <= 0.01) in relapsed samples 







Figure 3.5.1: Relapse-specific DE lncRNAs from BCP-ALL subtypes. 
A-C. Heatmap depicting the hierarchical clustering on relapse-specific DE lncRNAs signature on Z-score transformed 
LIMMA normalized expression values from DUX4, Ph-like and NH-HeH subtypes. Each heatmap shows the up and 
down-regulated lncRNAs specific to ID and REL samples. D. Molecular pathway analysis with the number of genes 
involved in each pathway from the enrichment analysis of the nearby (< 100 kb proximity) cis protein-coding genes 
correlated (Pearson correlation > 0.55 and P-value <= 0.05) with relapse-specific DE lncRNAs in the DUX4 subtype. 
The legend box indicates the number of ID and REL samples within each group. CAMs: Cell adhesion molecules. E. 




These relapse-specific lncRNAs signature consisted of 14 lncRNAs up-regulated in the Ph-like subtype 
and 26 DE relapse specific lncRNAs in the NH-HeH subtype, whereas in the DUX4 subtype we found 
146 relapses specifically up-regulated lncRNAs (Figure 3.5.1 A-C). The majority of dysregulated 
relapse-specific lncRNAs observed in our analysis are novel lncRNAs. However, we found 10 lncRNAs 
from our dysregulated set that had been reported in another disease including a different type of cancers 
(Table 3.5.8, Figure 3.5.2 A-C). In addition to that, we identified 61 relapse-specific (Appendix D) 
lncRNAs are significantly overlapped (Hypergeometric test P-value = 2.6 x 10e-4) with a recently 
published prognostic markers (Ali et al., 2018) lncRNAs from various cancers. 
 
 
Figure 3.5.2: Relapse-specific lncRNAs markers identified in other cancers. 
A. The boxplot represents, examples of relapse-specific lncRNAs, SLC38A3 (absolute fold change = -1.961, P-value = 
7.14 x 10e-4), LINC00312 (absolute fold change = -1.028, P-value = 1.69 x 10e-3) and ZBTB11-AS1 (absolute fold 
change = -1.55, P-value = 9.58 x 10e-3) which are significantly up-regulated in relapse samples compared to diagnosis 
samples in DUX4 subtype. B. The boxplot represents, examples of relapse-specific lncRNAs MIR17HG (absolute fold 
change = -0.82, P-value = 7.81 x 10e-4) and RP11-419K12.1 (absolute fold change = -1.18, P-value = 1.80 x 10e-3) 
which are significantly up-regulated in relapse samples compared to diagnosis samples in Ph-like subtype. C. The 
boxplot represents, examples of relapse-specific lncRNAs MBNL1-AS1 absolute fold change = -1.95, P-value = 5.62 x 
10e-4), CTA-445C9.14 (absolute fold change = -1.90, P-value = 2.59 x 10e-3) and RP1-153G14.4 (absolute fold change 
= -1.40, P-value = 5.34 x 10e-3) which are significantly up-regulated in relapse samples compared to diagnosis samples 











Chromosomal translocations T-cell leukaemia/lymphoma 
LINC00312 
(DUX4, Ph-like, NH-HeH) 
Proliferation, invasion, and migration of thyroid cancer, Nasopharyngeal 
carcinoma 
miR-17-92a-1 
(DUX4, Ph-like, NH-HeH) 
Development, progression, and aggressiveness of colorectal cancer 
Table 3.5.8: The differentially expressed lncRNAs between relapse (REL) and initial diagnosis (ID), from three 
subtypes, which were previously reported for its disease association, selected representative examples from relapse-
specific lncRNAs, which are previously identified in other diseases. Representative examples from ten disease-
associated lncRNAs 
3.5.1  Functional analysis for relapse-specific lncRNAs as markers of BCP-ALL subtypes 
We then aimed to infer the putative global molecular functions associated with these relapse-specific 
lncRNAs. For each subtype, we used the previously defined guilt-by-association approach to predict the 
putative functional pathway involved. Relapse-specific lncRNAs within Ph-like and NH-HeH subtypes 
did not show any significant correlation with activation of pathways. In contrast, we identified 56% (n = 
321) relapse-specific lncRNAs within the DUX4 subtype correlated with their cis PC genes. These 
strongly correlated relapse-specific lncRNAs showed activation of PC genes involved in vital signaling 
pathways and metabolic pathways. For example, Hippo, mTOR, and MAPK signaling pathways, cell 
adhesions molecule (CAMS) and metabolic pathways (number of genes involved >= 3 and P-value <= 
0.05) (Figure 3.5.1 D). These pathways are comparable to the identified pathways from the subtype-
specific analysis. Taken together, the results indicate that relapse-specific markers from DUX4 subtype 
may be functionally engaged in metabolic and signaling pathways (Figure 3.5.1 D). 
3.6  DNA Methylation Patterns of lncRNA genes are altered in BCP-ALL subtypes 
In order to analyze the methylation status of loci located at the lncRNAs genomic position in the BCP-
ALL subtypes, we used DNA methylation array data (collected from Illumina 450k methylation array) 
from the same patients (n = 45) included matched diagnosis (ID) and relapse (REL) samples (n = 82). 
Consistent with the RNA-seq dataset, the unsupervised clustering (PCA) on the DNA methylation profile 







Given these findings, we next looked into the differential hypo-methylated (Methylation value < 0; P-
value <= 0.05) and hyper-methylated (Methylation value >0.2; P-value <= 0.05) CpGs associated with 
lncRNAs between each subtype (Figure 3.6.2 A-C). We identified 1118 DM lncRNAs from three 
subtypes, with methylation distribution of 29.25% at promoter-TSS, 46% in the intronic and intergenic 
region and renaming in the gene body of the genome. About 10% of promoter-TSS methylated lncRNAs 
displayed a significant inverse correlation with its RNA expression level.  In the DUX4 and NH-HeH 
subtypes the number of hypo-methylated lncRNAs (differential methylation value < 0, P-value <= 0.05) 
were higher compared to the number of hyper-methylated lncRNAs. Whereas in Ph-like subtype the 
hyper-methylated (67%) lncRNAs were higher than hypo-methylated (33%) lncRNAs. 
We then explored the differentially methylated regions associated with lncRNAs and annotated them 
based on their genomic position. The differentially methylated CpGs were located in different genomic 
positions. In each subtype, we identified an average of 28% of DM lncRNAs in the promoter-TSS region 
(defined as region between -2000 base pair to +2000 base pair within TSS) the remaining within gene 
body (exon, and Transcription termination site (TTS), Figure 3.6.2 A-C (right panel). 
 
Figure 3.6.1: Hierarchical clustering of CpG's associated with DM lncRNA 
A. PCA of CpG's associated with lncRNAs on DNA methylation SWAN normalized beta values. Each point represents 











A. The heatmap representing hierarchal clustering on 544 differentially methylated (DM) CpG's associated with 434 
lncRNAs in DUX4 subtype. In the DUX4 subtype, we identified 328 (76%) differentially hypo-methylated and 106 
(25%) hyper-methylated lncRNAs. B. The heatmap representing hierarchal clustering on 518 DM CpG's associated with 
450 lncRNAs in the Ph-like subtype. In Ph-like subtype, we observed 302 (67%) hyper-methylated lncRNAs and 148 
(33%) hypo-methylated lncRNAs. C.The heatmap representing hierarchal clustering on 295 DM CpG's associated with 
234 lncRNAs in NH-HeH subtype. In the NH-HeH subtype, we identified 200 (86%) hypo-methylated and 34 (14%) 
hyper-methylated lncRNAs. The heatmap is plotted using SWAN normalised Methylation values. The bar plots below 
each heatmap represent the distribution of DM lncRNAs in the genome (Promoter-TSS and gene body) lncRNAs from 
each subtype. The distribution DM Promoter-TSS lncRNAs are as follows: 25%, 29% and 39% in DUX4, Ph-like, and 
NH-HeH subtype, respectively. The promoter methylated lncRNAs, we identified a higher degree of hypo-methylated 
and lower number hyper-methylated lncRNAs in DUX4 and NH-HeH subtypes. However, the Ph-like subtype has 
shown a higher degree of hyper-methylated DM lncRNAs than hypo-methylated DM lncRNAs. 
3.6.1  Correlation between subtype-specific differentially expressed and differentially 
methylated lncRNAs 
In order to systematically define epigenetically silenced or facilitated lncRNAs in the three subtypes, we 
correlated the expression FPKM and the beta value of promoter-TSS DM lncRNAs. We identified 6.7% 
of lncRNAs with hyper-methylated and hypo-methylated promoters with a reduced or increased RNA 
expression level within BCP-ALL subtypes. For instance, in the DUX4 subtype, 17% (n = 22) of DM 
lncRNAs at promoter region (Differential hyper-methylation > 0.2; Differential hypo-methylation < 0; 
P-value <= 0.05) were differentially expressed (P-value <= 0.01 and Absolute fold change = +- 1.5). Out 
of that, 15 lncRNAs were significantly inversely correlating with their RNA expression levels (Pearson 
correlation test, two-tailed P-value <= 0.05, Figure 3.6.3 A). Whereas in the Ph-like subtype, 9% (n = 11) 
of significantly DM lncRNAs at promoter region (Differential hyper-methylation > 0.2 ; Differential 
hypo-methylation < 0; P-value <= 0.05) are differentially expressed (P-value <= 0.01 and Absolute fold 
change  =+- 1.5), and out of that we found 73% (n = 7) lncRNAs with a significant inverse correlation 
with their RNA expression level (P-value <= 0.05, Figure 3.6.2 D). Analogously, in the NH-HeH subtype 
we observed three promoters associated lncRNAs overlapping with the DE signature, where 2 out of 3 
showed a significant anti-correlation to their expression level. 
Thus, the DM promoter-TSS methylated lncRNAs harboring statistically significant DM at promoter 
regions, and the strong anti-correlation with its expression level collectively determined 23 putative 
epigenetically facilitated and silenced lncRNAs from our three BCP-ALL subtypes (Table 3.6.9). 
Table 3.6.9: The list of significantly correlated DNA methylation and the expression for promoter methylated 










AC003075.4 -0.31 0.004 1.43 -1.26 
DUX4 




AC104655.3 -0.26 0.017 -2.27 2.07 
CACNA1C-AS1 -0.45 2.03E-05 1.97 -1.62 
CTB-25B13.9 -0.26 0.016 -1.73 1.46 
IGF2-AS -0.24 0.028 -1.33 4.95 
LINC01006 -0.39 0.001 -2.06 2.53 
PVT1 -0.40 0.001 -2.13 1.15 
RGMB-AS1 -0.26 0.0193 -1.48 5.96 
RP11-125B21.2 -0.35 0.001 -1.75 4.11 
RP11-138M12.1 -0.70 5.21E-13 -5.98 3.77 
RP11-367G6.3 -0.30 0.004 1.98 -1.63 
RP11-624M8.1 -0.50 1.34E-06 -3.34 4.13 
RP11-789C17.3 -0.36 0.001 -2.27 3.2 
SERTAD4-AS1 -0.25 0.0232 -1.98 1.79 
LINC01006 -0.38 0.0003 1.44 -1.56 
Ph-like 
RP11-138M12.1 -0.70 5.21E-13 2.06 -1.44 
RP11-305F18.1 -0.64 5.36E-11 1.76 -2.08 
AC099754.1 -0.33 0.002 1.21 -1.36 
ACVR2B-AS1 -0.36 0.0009 2.18 -1.75 
LINC00996 -0.39 0.0003 -1.56 2.11 
ERICH1-AS1 -0.40 0.0006 -1.82 2.21 
DIO3OS -0.31 0.0037 -1.76 4.05 
NH-HeH 
U3 -0.83 1.346E-22 -2.01 2.43 
Table 3.6.9: The lncRNAs are promoter differentially methylated and correspondingly differentially expressed. DM: 
Differentially methylated. The significance is calculated based on Pearson correlation rate and two -tailed P-value <= 
0.05. 
 
Of these 23 epigenetically modulated lncRNAs, we observed novel lncRNAs to show an anti-correlation 
between the DNA methylation rate and expression levels. For instance, in the DUX4 subtype, lncRNA 
R11-138M12.1 and RP11-624M8.1, showed a significant hypo-methylated at their promoter region and 
is transcriptionally up-regulated in the DUX4 subgroup (Pearson correlation coefficient = -0.69; P-value 
= 5.1E-13 for R11-138M12.1; Pearson correlation coefficient = -0.50; P-value = 1.36E-06 for RP11-
624M8.1; Figure 3.6.2 B -C). The same lncRNA R11-138M12.1 showed significant hypermethylation at 
the promoter region and a concordant down-regulation in the Ph-like subgroup (Figure 3.6.2 E). 
Besides the novel lncRNAs, we identified certain others lncRNAs which are previously brought in the 
context of different cancers from our epigenetically facilitated set. The lncRNA PVT1 is an example 
which we observed in the DUX4 subtype with significant anti-correlation (P-value <= 0.01) to its 
expression level. These findings suggest that epigenetic silencing of lncRNAs may be a mechanism that 











A. The barplot depicts the distribution of hyper and hypo-methylated LncRNAs in promoter region. B-C. The 
promoter-TSS DM lncRNAs with significant negative correlation with DE expression profile from the DUX4 
and Ph-like subtypes. D. Two representative examples of hypo-methylated lncRNAs with increased expression 
profile from a DUX4 subtype with significant inverse correlation between DNA methylation and expression 
levels. The lncRNA RP11-138M12.1 (Pearson correlation coefficient = -0.69, 2-tailed P-value = 5.21e-13), 
RP11-624MB.1 (Pearson correlation coefficient = -0.50, P-value = 1.36e-06) are examples with hypo-
methylation and up-regulated expression pattern. E. A representative example of the promoter hyper-
methylated lncRNA, RP11-138M12.1 (Pearson correlation coefficient = -0.69, 2-tailed P-value = 5.21e-13) 
with down-regulated expression pattern, and with inverse correlation within the Ph-like subtype. 
3.6.2  Chromatin markers associated with intronic and intergenic methylated subtype-specific 
lncRNAs 
Around 46% (n = 512) of the DM subtype-specific lncRNAs are localized in the intronic and intergenic 
genomic regions. We next aimed to investigate whether these lncRNAs regions have chromatin markers 
encoded within their genomic location. A recent human genome-wide chromatin marker study (114) has 
provided us with a rich resource to identify chromatin markers. Genome-wide mapping of B-lymphocyte 
cell line by searching for epigenetic markers within our DM subtype-specific intronic and intergenic 
regions revealed a significant number of lncRNAs (n = 53, Fisher extract test P-value = 2.2E-16) with 
enhancer and insulator markers. Out of these, lncRNAs, RP11-134O21.1, RP11-398B16.2, RP11-
689B22.2, CTC-458I2.2, and LINC00880 were DE expressed, with a significant negative correlation 
between DNA methylation and expression levels in the DUX4 subtype (Table 3.6.10). Together these 
show both intronic and intergenic DM lncRNAs associated with strong enhancer and insulator regions 
can accelerate its expression at the epigenetic level. 
Table 3.6.10: The list of significantly correlated DNA methylation and expression for intronic and Intergenic 









P-value Epi-markers Biotype 
RP11-134O21.1 2.54 -1.56 -0.63 1.9E-010 Enhancer  
Intron 
RP11-398B16.2 2.08 -1.85 -0.47 0.0007 Insulator 
RP11-689B22.2 1.52 -3.37 -0.47 0.008 Enhancer 
CTC-458I2.2 -1.16 3.38 -0.42 0.0001 Enhancer 
LINC00880 -1.45 2.23 -0.25 0.02 Enhancer Intergenic 
 
Table 3.6.10: The significance is calculated based on Pearson correlation rate and two -tailed P-value <= 0.05. The 
lncRNAs are promoter differentially methylated and differentially expressed in their corresponding subtypes. These 
lncRNAs are with enchancer and insulator epigenetic markers. DM: Differentially methylated. 
 
We further compared our list of DMR associated lncRNAs from each subtype with published list disease-
associated lncRNAs and identified 24 previously reported disease associated lncRNAs (Table 3.6.11) 





Table 3.6.11: The list of DM lncRNAs which are previously reported due to there disease associations (n = 24) 
from BCP-ALL subtypes. 
DM Subtype-specific lncRNAs Subtypes Annotation Methylation value P-value 
ADAMTS9-AS2 Ph-like intron 1.777801 0.00171869 
DANCR NH-HeH promoter-TSS -1.787494 0.02195348 
DLEU2 NH-HeH intron -1.857272 0.007403689 
DLX6-AS1 DUX4 Intergenic -1.639343 0.007447799 
 NH-HeH intron -1.368489 0.03913844 
EGOT Ph-like intron -1.995476 0.01631441 
ERICH1-AS1 DUX4 intron -2.788796 0.0000274 
NH-HeH intron -2.396816 0.0002673425 
FENDRR NH-HeH intron -1.742717 0.004852748 
HOTAIRM1 DUX4 promoter-TSS -1.858395 0.0002810779 
Ph-like promoter-TSS 1.428301 0.0202788 
HOXA-AS2 NH-HeH promoter-TSS -1.509447 0.02797619 
HOXA11-AS NH-HeH Promoter-TSS -1.84395 0.001730609 
Ph-like exon -1.934465 0.02145395 
IGF2-AS 
 
DUX4 Promoter-TSS -1.326866 0.0322549 
NH-HeH Promoter-TSS -1.405105 0.03537591 
KCNQ1OT1 Ph-like exon 2.251927 0.008248937 
LINC00261 Ph-like intron -2.112499 0.01462022 
LINC00467 DUX4 promoter-TSS 2.000734 0.0018457 
LINC00473 DUX4 promoter-TSS -1.442647 0.02018019 
MEG3 DUX4 intron -2.518794 0.0001154195 
NEAT1 DUX4 exon 2.230128 0.000287578 
Ph-like exon -1.787521 0.01741656 
PVT1 DUX4 Promoter-TSS -2.126776 0.0009309612 
Ph-like Promoter-TSS 1.960143 0.002582014 
RGMB-AS1 DUX4 Promoter-TSS -1.471133 0.007150467 
RP11-325I22.2 NH-HeH Intergenic -1.778581 0.02285671 
TCL6 DUX4 Promoter-TSS 1.749096 0.006956922 
Ph-like intron 1.844357 0.04590776 




UCA1 DUX4 intron -4.572273 0.000000778 
Ph-like intron 2.03285 0.02043621 
ZNRD1-AS1 Ph-like Promoter-TSS 1.679822 0.01186042 
Table 3.6.11: The list of previously reported lncRNAs which are associated with other disease including leukemia 
identified within our DM subtype-specific lncRNAs. For example, HOTAIRM1, previously reported to be associated 






Chapter 4.  Discussion 
BCP-ALL is a genetically heterogeneous disease consisting of many subtypes. Understanding the 
molecular signature behind these subtypes could improve its diagnosis and treatment. In the recent past, 
compared to protein-coding genes, there is a growing appreciation for investigating the role of lncRNAs 
in cancer development and progression given their surprising functions and their aberrant gene 
expression patterns. Now, it is apparent that lncRNAs are involved in the tumorigenesis of leukemias. 
Nevertheless, a comprehensive characterization of the transcriptome, DNA-methylation, and their 
functional contribution in distinct BCP-ALL subtypes are lacking. 
Unsupervised clustering of lncRNAs expression and DNA methylation profile demonstrated the ability 
of lncRNAs in classifying the established BCP-ALL subtypes within our cohort. This finding was further 
subsequently validated in an independent validation cohort of 47 patients. In addition to that, we 
cataloged a comprehensive set of 1564 subtype-specific and 941 relapse-specific lncRNAs using RNA-
Seq data. Finally, we present a catalog of 1118 differentially methylated lncRNAs based on the DNA 
methylation array data from the same patients across the three subtypes. In addition, to that we highlight 
23 lncRNAs whose expression levels were epigenetically facilitated or silenced. 
Interestingly, 36% of DUX4 and Ph-like specific lncRNAs (n = 229) and 62% (n = 321) of relapse-
specific lncRNAs within DUX4 were found be associated with pivotal signaling and metabolic pathways 
relevant to the progression of ALL. We present a catalog of lncRNAs based on an integrative analysis 
which brought significant insight and advances over previous studies as it provides the most 
comprehensive dataset and their potential functions in BCP-ALL, a resource of clinically relevant 
relapse-specific lncRNAs signature and discloses their utility in prognosis. 
The discussion part is divided into two sessions the first section discusses the methods used in the thesis 
and in the second part, I evaluate the major results. One of the challenges of this thesis was to determine 
the best practices for our RNA-Seq data analysis. Our first goal was to determine right algorithms which 
addresses all the major caveats of the datasets in order to draw reliable conclusions. In the following 




4.1  RNA-seq for determining the subtype-specific and relapse-specific lncRNAs 
RNA-Seq technology revolutionized the study of transcriptomes. RNA-Seq allows the detection and the 
quantification of expressed genes or transcripts in a biological sample. RNA-Seq has clear advantages 
over previously existing technologies, such as microarray and Sanger sequencing. For example, 
microarray relies upon existing knowledge about genome sequence, high background levels owing to 
cross-hybridization and a limited dynamic range of detection owing to both background and saturation 
of signals. Unlike, former technologies, the RNA-seq approach is not limited to detecting known 
lncRNAs, but is also able to identify novel lncRNAs that are present in the human genome. (Zhong Wang, 
Gerstein, & Snyder, 2009). Owing to the rapid decrease in sequencing costs, RNA-seq may soon replace 
microarrays completely. However, choosing the right alignment tool is always is the key to RNA-Seq 
data analysis for maximum detection of significant genes involved in BCP-ALL samples. With the onset 
of RNA-Seq technology, there are some tools and methods developed for the RNA-seq sequence 
alignment. The appropriate mapping and read quantification algorithm were chosen based on their 
capabilities to address existing constrains. This enabled extraction of reliable information out of raw 
RNA-seq data. 
In certain instances, we observed increased misalignment of spliced reads or junction reads for lncRNAs. 
This was true for antisense and sense lncRNAs. For example, the read sequences mapping to the exon-
exon junction of lncRNAs were borrowed from their sense of PC genes, resulting in increased 
misalignment. Inherent problems of all de novo RNA-seq aligners including, Tophat and cufflinks, are 
its inability to accurately detect the splicing events or junction reads that are in the short sequence on the 
junctions. Therefore, this problem increases the under-detection of splicing events or increases the 
misalignment rate. 
A recently developed aligner, STAR-align provided solutions for the above issues combined with faster 
performance. STAR-align mitigates this problem by its 2-pass option in which it first obtains information 
about possible splice junction loci from annotation databases. Then it is also possible to run a second 
mapping pass, supplying it with novel splice junction loci found in the first mapping pass. In the second 
pass, STAR will not discover any new junctions but will align spliced reads with short overhangs across 
the previously detected junctions. The STAR-align takes the splice junction reads into accounts by its in-
built parameters. Additional reasons for using STAR-align tool was due to its better mapping accuracy 
(sensitivity and precision) and computational resources (runtime and disk space) compared to former 
mapping tools (Dobin et al., 2013). We, therefore, decided to finalize STAR-align for our RNA-seq 




4.2  Transcriptome alignment and read quantification 
The transcriptome is the complete set of the transcript in a cell for a specific developmental stage or 
physiological condition. Studying the transcriptome is essential for interpreting the functional elements 
of the genome and revealing the molecular constituents of cells and tissues, and also for understanding 
developments that are attributable to the disease. LncRNAs have complex patterns of expression and 
regulation compared to PC genes. Like RNA-seq reads alignment, determining the quantities of these 
reads were also challenging. The major challenge was ambiguous read mapping due to close paralogs 
present in the genome and the generally low expression level of lncRNAs. In addition to that our data set 
is strand non-specific RNA-seq data composed the second challenge in the work-flow construction to 
determine the useful tool for read quantification or extracting the gene expression count. 
When the dataset is strand non-specific the gene expression quantification of some subtypes of lncRNAs 
other than lincRNAs is not possible, as they may share sense and antisense sequence with PC genes with 
overlapping exons. When there are a sense and antisense overlapping gene across a given lncRNAs gene 
body, the tendency of borrowing reads from these neighboring partners would increase, and therefore an 
accurate estimation of the exact gene expression level is not possible. The StringTie (transcriptome 
assembler) algorithm overcame this issue with its final transcriptome assembly and read quantification 
solution, regardless of the non-strand specificity of our reads. The StringTie algorithm accurately 
quantified reads which are mapped in splice junctions or exon-exon junction of each lncRNAs without 
borrowing its neighboring reads from the sense protein-coding genes. To test the ability of StringTie with 
different other programs which quantify gene expression we tested feature-count, and Ht-seq. These tools 
resulted in biased results for the sense and antisense lncRNAs. In addition to that, the output files from 
StringTie can be processed by R Bioconductor differential expression analysis programs like Deseq2, 
edgeR, LIMMA Voom. Whereas other similar transcriptome assemblers (example Cufflinks), need one 
more additional step of read quantification using other tools like Ht-seq. Therefore, using StringTie 
enabled us to reduce the complexity of characterizing antisense or partially intronic transcripts from our 
strand unspecific RNA-Seq libraries. StringTie had fast run, which is several times faster than Cufflinks 
(our former tool of choice), HTSeq (Anders, Pyl, & Huber, 2014), and FeatureCount (Liao, Smyth, & 
Shi, 2014). 





Accurate detection of significant differentially expressed genes is one of the essential steps in RNA-seq 
work-flow. RNA-seq data is heteroscedastic in nature, meaning that, some genes have a higher variance 
than others. However, the ultimate rationale in the choice of the tool for DE analysis is based on ability 
of an algorithm which could leverage all caveats present in the datasets. In our case, we had 82 samples 
from 45 patients, from 2 disease stages with corresponding matching diagnosis (primary sample) and 
relapse from each patient. However, for 8 individual patients, we had either of ID or REL samples. And 
DESeq2 has no statistical function to leverage this sample imbalance and biological dependency or 
confounders. The differential expression analysis using R-Bioconductor, LIMMA Voom, accommodates 
the mean-variance relationship using precision weights calculated by the Voom function and has 
additional features to accommodate the co-founders within our dataset. 
4.4  Functional enrichment analysis of lncRNAs 
The high throughput technologies have enabled a detailed exploration of lncRNAs in different diseases. 
Functional association of lncRNAs is a daunting task, due to low expression rate, and cell or tissue-
specificity. However, the functional role, if any, of these lncRNAs, are largely unexplored. Unlike 
protein-coding genes, lncRNAs have no functional databases like DAVID, reactome, or Panther. 
Recently, there are methods like “guilt-by-association” approach is used to identify potential functions 
of lncRNAs. By systematically applying this approach we defined the functions of our subtype-specific 
and relapse-specific lncRNAs. The approach is based on the hypothesis described in several earlier 
studies, that lncRNAs exert their functions by regulating neighboring (cis) and distally (trans) located 
protein-coding genes. The correlation-based “guilt-by-association” approach is based on the hypotheses 
that co-expressed genes are more likely to be co-regulated, or share the same functions. Compared to 
other methods, including genome-wide-clustering, which is based on hierarchical clustering, L-means 
and self-organizing maps (SOMs) require some form of a selection of cluster number or size. Therefore, 
these methods require careful selection of parameters to ensure that the clusters obtained would result in 
reliable conclusions. The network approach is another method similar to clustering approach, which is a 
computationally difficult task, even though there exist several algorithms and statistical approaches for 
this purpose. 
Functional enrichment analysis is mostly done using the database. For example, Database for Annotation 
Visualization and Integrated Discovery (DAVID) (Huang, Sherman, & Lempicki, 2008), and Gene Set 




drawback of such tools is since these databases are growing dramatically and it becomes more difficult 
for those enrichment tools to include that updated information. Therefore, the need for an enrichment 
tool which performs the real-time analysis is required. We used Gene Set Clustering based on Functional 
annotations (GeneSCF) for the functional enrichment analysis. GeneSCF is a relatively new tool which 
performs real-time functional enrichment analysis. GeneSCF makes use of source databases directly 
while enrichment analysis is performed. This tool is a more reliable compared to its predecessors mainly 
because of its real-time analysis nature (Subhash & Kanduri, 2016). 
4.5  DNA methylation array on subtype-specific lncRNAs profiling 
We used Illumina's Infinium HumanMethylation450 BeadChip for profiling lncRNAs within our BCP-
ALL samples. Compared to the current methods for genome-wide DNA methylation profile such as 
tilling microarrays and bisulfite genomic DNA sequencing of selected regions, the Illumina's Infinium 
HumanMethylation450 BeadChip has its advantages. For instance, these methods (tilling micro-arrays 
and bisulfite genomic DNA sequencing) require large amounts of sample material and labor, making it 
difficult to use in large-scale studies where there is a limited number of samples are used. The Infinium 
HumanMethylation450 array makes it possible to assess the methylation status of >450 000 CpGs located 
throughout the genome, which means it covers 96% of CpG or known as CGIs (regions where cytosine 
nucleotide is followed by guanine nucleotide, separated by a phosphate group) islands within the 
genomes, offering a comprehensive coverage with high-throughput compatibility to large sample size 
(Dedeurwaerder et al., 2014). The signal intensity is measured using an Illumina scanner (iScan) to 
generate the beta values. 
4.6  Unsupervised hierarchal clustering revealed lncRNAs expression and 
methylation pattern correlated with established molecular subtypes of BCP-
ALL 
Unsupervised hierarchal clustering of lncRNAs expression and DNA methylation data identified the 
robust classification of previously established BCP-ALL subtypes from 45 relapsed patients. Emerging 
evidences have shown that lncRNAs can be used as a classifier in the molecular subtypes of different 
solid tumors, including, ovarian cancer, glioma, and lung squamous cell carcinoma (Du et al., 2013). Of 
the few studies performed in leukemias, most have analyzed the association of lncRNAs in AML (Lei et 
al., 2017) and pediatric ALL (Gioia et al., 2017) classification there are no much comprehensive studies 




from different age groups of both pediatric and adult cases. This observation was true for DNA-
methylation dataset and 1534 subtype-specific and 1118 differentially methylated lncRNAs. Taken 
together, our analysis provides insights of lncRNA-based stratification of BCP-ALL patients on the 
established molecular subtypes of ALL. 
4.7  Validated set of BCP-ALL subtype-specific lncRNAs 
We further corroborated the ability of lncRNAs to classify the established molecular subtypes in an 
already processed independent validation cohort of 47 BCP-ALL patients.  In line with our observation, 
we identified similar clusters of molecular subtypes based on lncRNAs expression profile in the 
independent validation cohort upon unsupervised hierarchical clustering. This result strengthens our 
preliminary observation that subtype-specific lncRNAs can be used as classifiers like PC genes in 
molecular subtypes of BCP-ALL. In-depth transcriptomic analyses using RNA-seq revealed that 
lncRNAs profiling could recapitulate the molecularly defined subtypes of BCP-ALL, which agrees with 
the findings of recent studies (W. Zhao, Luo, & Jiao, 2014). 
4.8  BCP-ALL subtype-specific lncRNAs showing oncogene properties like drug 
resistance 
Besides the subtype-specificity, we also identified previously detected/described lncRNAs within our set. 
A closer look at these molecular subtype–specific lncRNAs identified 23 lncRNAs previously validated 
and reported as onco-lncRNAs in different cancers including leukemia. The representative examples of 
these onco-lncRNAs in the subtypes are discussed in the following session. For example, tumor 
suppressor GAS5 is up-regulated in the DUX4 subtype; it has been reported to be related to cell-cycle 
arrest and apoptosis properties in other cancer types (Nobili et al., 2016). Recently, an isoform of GAS5 
lncRNAs (GAS6-AS2) (Bester et al., 2018) is reported to be associated with chemotherapy resistance in 
AML. However, there are no direct reports of GAS5 in BCP-ALL subtypes. Notably, the highly expressed 
MIR155HG lncRNA mainly associated with B-cell malignancies (CLL) and B-cell receptor signaling 
was down-regulated within the DUX4 subtype (Vargova et al., 2011). MIR155HG associated with 
aggressive phenotype in cytogenetically normal acute myeloid leukemia (CN-AML) was found to be 
down-regulated in DUX4 subtype compared to others. Another example is lncRNA PVT1, which is 
widely reported in AML is up-regulated in the DUX4 subtype. The lincRNA MIAT up-regulated in Ph-
like subtype within our cohort, over-expression of MIAT is reported to be associated with CLL (Sattari 




differentiation and apoptosis in AML is up-regulated Ph-like subtype. Besides, the known lncRNAs, we 
have identified novel lncRNAs as BCP-ALL subtype-specific lncRNAs. Taken together, these subtype-
specific lncRNAs signature from different molecular subtypes may serve in defining the core lncRNAs 
that orchestrate the key oncogenic properties of BCP-ALL subtypes. 
4.9  Relapse-specific lncRNAs markers in BCP-ALL subtypes 
A hand full of studies consistent with our studies reported the role of lncRNAs in relapse and its 
importance as prognostic factor (Zhonghao Wang, Wu, Feng, Zhao, & Tao, 2017) in several cancer types 
(Ali et al., 2018). However, so far there are no studies reporting relapse specific lncRNAs in BCP-ALL 
subtypes. Like protein-coding RNAs, several lncRNAs are reported as markers of other diseases.  In our 
analyses, we found associations between lncRNAs and relapse on three different subtypes of BCP-ALL. 
One of the leading causes of death in ALL patients is the disease relapse. Chemotherapy resistance of 
relapsed blasts compared to what is observed in diagnosis is a key hallmark of ALL relapse. Innovative 
strategies are urgently required due to the frequent failure of conventional salvage chemotherapy, 
including intensified drug schedules and stem cell transplantation, in the treatment of relapsed ALL 
(Bhatla et al., 2014). Thus, there is always a great interest in characterizing the molecular drivers of 
relapsed ALL because it has a poor outcome with conventional therapy and is increasing with age 
(Iacobucci & Mullighan, 2017). 
We cataloged a comprehensive set of 941 relapse-specific lncRNAs which are driving the BCP-ALL 
progression. Initially, we looked for relapse-specific lncRNAs in adults and pediatric patients. Due to the 
heterogeneity of BCP-ALL, we could not infer any significant relapse-specific lncRNAs and thus 
investigated relapse-specific lncRNAs signature within each subtype. Within each subtype, we found that 
the relapse-specificity of lncRNAs was more pronounced than in the whole cohort (n = 82). Interestingly, 
when compared to relapse-specific mRNA signature the relapse-specific lncRNAs signature was stronger 
with clear separation between ID and REL samples for all three subtypes. Gene expression profiling of 
leukemic blasts in the matched diagnosis and relapse patient pairs in protein-coding genes has revealed 
a common gene signature reflective of relapse, gene markers involved in proliferation and cell cycle 
regulation, apoptosis, DNA repair and drug resistance (Bhatla et al., 2014). However, lncRNAs based 




4.9.1  Relapse-specific onco-lncRNAs 
Although the majority of the relapse-specific lncRNAs identified were novel ones, we identified a hand 
full of previously defined onco-lncRNAs. The examples included MIAT, CCDC26, TCL6, RP11-
701P16.5, MIR503 Host Gene (MIR503HG), MIR17HG and GAS5, with cell-cycle arrest and apoptosis 
properties in cancer (Kitagawa et al., 2013). In the DUX4 subtype, we observed lncRNAs, T-cell 
leukemia/lymphoma 6 (TCL6), which was up-regulated in diagnosis compared to relapse. TCL6 is 
reported to its leukemogenesis properties in T cell leukemia (H. et al., 2017). However, its association 
with BCP-ALL is not documented, and its functions are unclear. The results of our “guilt-by-association” 
study highlights its association with the PI3K-Akt signaling pathway in DUX4 subtype. 
Other examples are, the BDNF antisense RNA (BDNF-AS) and Insulin-like growth factor 2 antisense 
(IGF2-antisense, embryonic stem cell-related (ESRG) are up-regulated in the diagnosis and LINC00312 
up-regulated in relapsed samples. Among the disease-associated lncRNAs, in Ph-like, we observed 
SNHG3 (a marker for malignant melanoma), as up-regulated in relapse stages. The lncRNAs 
AP000688.29 was down-regulated and MIR17HG was up-regulated in relapse. The lncRNA 
MIR17HG46 was reported to suppress apoptosis in myc-driven lymphomas (Ott, Rosenwald, & Campo, 
2013) and was DE in relapse compared to diagnosis samples within the Ph-like subtype. In NH-NeH 
subtype we observed AP000688.29 and IFNG-AS1 as down-regulated, whereas MBNL1 antisense RNA 
1 (MBNL1-AS1), CTA-445C9.14 and RP1-153G14.4 were up-regulated in relapse samples. Overall, the 
relapse-specific lncRNAs highlights the oncogenic relevance in BCP-ALL subtypes. 
4.9.2  Relapse-specific lncRNAs as prognostic markers 
Besides the oncogenic properties, lncRNAs can act as prognostic markers and aid for disease diagnosis 
and treatment (Ali et al., 2018).  We identified a significant enrichment of a subset of relapse-specific 
lncRNAs (n = 61) with recently identified independent prognostic markers from 14 different solid cancer 
types. Out of these, for example, lncRNA LUCAT1 was previously reported for its role in drug resistance 
in solid cancer (Z. Han & Shi, 2018). Within the DUX4 subtype, we identified up-regulated expression 
of LUCAT1 at relapse, providing a novel insight into treatment resistance for BCP-ALL subtypes. 
Together, this illustrates that the catalog of relevant lncRNAs in different subtypes of BCP-ALL serves 
as subtype-specific and relapse-specific markers with the potential of RNA based treatments for BCP-
ALL subtypes. 





The subtype-specific and relapse-specific lncRNAs showed significant correlation between genes 
enriched in key pathways associated with cell proliferation, growth, survival, metabolism, and autophagy 
based on the correlations with their neighboring and distinct protein-coding genes. These findings 
indicate that BCP-ALL subtype-specific and relapse-specific lnRNAs are associated with tumorigenesis 
of hematopoietic cells. LncRNAs are emerging as new players in cancer, due to their potential roles in 
both oncogenic and tumour suppressive pathways. They are frequently dysregulated in a variety of 
human cancers; however, the biological functions of a vast majority of them remain unknown. Recently, 
evidence of lncRNAs molecular mechanisms and function has begun to accumulate, providing insight 
into the functional roles they may play in tumorigenesis (Serviss, Johnsson, & Grandér, 2014). 
The guilt-by-association method designates potential or putative functions to lncRNAs based on its co-
expression of characterized PC genes. The certainty of the association is based on the condition of 
available expression data. For instance, time-dependent data can be notably crucial because aberrant 
regulation of expression can be informative of the certain pathways by which lncRNAs functions 
(Bartonicek, Maag, & Dinger, 2016). Our study consists of time-dependent dataset from two disease 
stages. The appropriateness and popularity of this approach have given rise to several subtypes of 
analyses including the cis and trans-correlation-based association. 
We identified a remarkable fraction of subtype-specific lncRNAs (621 out 1534) with significant co-
expression with their cis and trans located protein-coding genes. Notably, 32% of these lncRNAs are 
involved in pathways associated with proliferation, apoptosis and differentiation in leukemia, including, 
JAK-STAT, mTOR, PIK3-AKT, TGF-beta, MAPK, P53, hippo and NF-kappa B signaling pathways from 
both DUX4 and Ph-like subtypes. The co-expression between the protein-coding genes and subtype-
specific lncRNAs provided a possible explanation of co-regulation or co-activation of lncRNAs, with 
their cis and trans PC genes. We also demonstrated that several lncRNAs were co-expressed with 
oncogenes associated with leukemias. 
4.10.1  Potential functions of DUX4 specific DE lncRNAs associated with signaling pathways 
In the DUX4 subtype, we report lncRNAs signature (n = 185, both cis and trans based analysis) 
associated with pathways reported to play a key role in leukemogenesis, such as TGF-Beta signaling 
pathway, P53, Endocytosis, hippo, proteoglycans, and pathways in cancer. Considering the functional 
nexus between these lncRNAs and leukemia related pathways, targeting these lncRNAs provide novel 




In ALL, TGFB has complex roles; it regulates the proliferation of the distinct myeloid stem cells (Dong 
& Blobe, 2006). Recently there are some lncRNAs documented to be associated with TGFB gene. For 
instance, Lnc-ATB, a TGFB2 induced lncRNA that could mediate TGF-β-induced epithelial-
mesenchymal transition and has been reported to promote metastasis in various solid cancer such as 
hepatocellular carcinoma, colorectal cancer, gastric cancer, and breast cancer. However, the lncRNAs 
associated with BCP-ALL subtypes are not reported. We identified the antisense lncRNA, RP11-
224O19.2 and other novel lncRNAs significantly correlated with TGFB, and are enriched in TGF-beta 
pathway, indicating their functional relatedness or regulatory relationships. Interestingly, the subtype-
specific lncRNAs and subtype-specific PC are globally predicted to activate or inhibit the same key 
signaling pathways in the DUX4 subtype. 
4.10.2  Potential functions of Ph-like specific DE lncRNAs associated with signaling pathways 
The Ph-like subtype is both molecularly and functionally well characterized based on mRNAs/protein 
expression levels, whereas non-coding genes are not much studied. We have identified a list of 24 novel 
dysregulated Ph-like specific lncRNAs crucial in signaling pathways associated with Ph-like subtype. 
The pathways controlling the cell proliferation, differentiation, and survival of hematopoietic cells were 
identified based on functional enrichment analysis, for example, the PI3K and mTOR signaling 
pathways. In addition to that, our functional predictions identified other prominent pathways which 
trigger chemotherapy resistance in BCP-ALL, including, JAK-STAT2, Cytokine-cytokine receptor and 
endocytosis pathways. The lncRNAs associated with these pathways are antisense or sense intronic to 
the mRNA genes with a significant co-expression pattern. Characterization of the lncRNAs involved in 
this pathway may be of interest in the search for new potential therapies. 
Some of the functions predicted here have been validated by previous studies, suggesting that our guilt-
by-association approach is valid. For example, lncRNA AC002454.1 was recently reported to regulate 
CDK6 to participate in cell cycle dysfunction in the endometriosis pathogenesis. LncRNA AC002454.1 
is an antisense lncRNA of CDK6 gene. The results of our guilt-by-association study highlight an 
association of this lncRNA with the PIK3-Akt pathway. Both the CDK6 gene and antisense AC002454.1 
are significantly co-expressed and up-regulated in the Ph-like subtype. 
Interestingly, we observed a significant co-expression between oncogene IL2RA and its antisense 
lncRNA RP11-536K7.5. Recently, IL2RA gene was found to be specifically up-regulated by pre-B cell 
receptor (pre-BCR) signaling during early B cell development, and cells with oncogenically activated 




et al., 2015). In Ph-like subtype, we observed IL2RA gene enriched in the cytokine-kinase signaling 
pathway. Both IL2RA and RP11-536K7.5 were up-regulated in Ph-like samples. The ability of IL2RA to 
stabilize oncogenic signaling strength in Ph-like ALL is important for leukemia initiation and 
development. Our analysis indicates the co-regulation or co-regulation of RP11-536K7.5 with IL2RA 
gene, which provided a new context for further characterization of RP11-536K7.5 lncRNA. We predicted 
the positive association between cytokine-kinase signaling pathway and RP11-536K7.5 lncRNA, but the 
mechanisms involved are still poorly understood, therefore, further studies are needed to better 
understand RP11-536K7.5/ cytokine-kinase signaling transduction. 
It was noteworthy that subtype-specific lncRNAs and subtype-specific PC are globally predicted to 
activate or inhibit the same pathways. However, some exclusivity appeared. For example, lncRNAs 
specific to the Ph-like subtype particularly involved in the activation of mTOR and the PI3K-Akt 
signaling pathway. Considering the functional nexus between Ph-like specific lncRNAs and the 
activation of pathways such as mTOR and PI3K signaling pathways, targeting those lncRNAs may be a 
promising novel therapeutic option for BCP-ALL subtypes provided a new context for further 
characterization of RP11-536K7.5 lncRNA. We predicted the positive association between cytokine-
kinase signaling pathway and RP11-536K7.5 lncRNA, but the mechanisms involved are still poorly 
understood, therefore, further studies are needed to better understand RP11-536K7.5/ cytokine-kinase 
signaling transduction. 
4.10.3 Molecular and functional association of relapse-specific lncRNAs signature 
We applied the “guilt-by-association” approach also on the relapse-specific lncRNAs markers within the 
subtypes for investigating their functions. However, the relapse-specific signature from the Ph-like and 
the NH-HeH subtypes did not show any significant enrichment of pathways. A potential reason can be 
that the DUX4 subtype is particularly perturbed in both relapse-specific and subtype-specific 
classification, and therefore the number of dysregulated lncRNAs are high compared to the other two 
subtypes. 
In the DUX4 subtype, a notable observation was a strong correlation between relapse-specific lncRNAs 
with genes involved in the activation of metabolic pathways and signaling pathways. We identified 112 
relapse-specific lncRNAs co-expressed with 29 PC genes activated in metabolic pathways. Out of this 
112 lncRNA, eight lncRNAs were previously reported as biomarker lncRNAs in the context of various 
cancers. For example, we identified oncogenic lncRNA LUCAT1 reported to be associated with poor 




pathways in the DUX4 subtype was previously reported due to their ability to dysregulate metabolic 
pathways in multiple tumor contexts. Taken together, the global co-expression analysis and gene-
expression profiling suggest important and previously unappreciated roles of lncRNAs in the BCP-ALL 
subtypes. 
4.11  Differentially methylated lncRNAs in BCP-ALL subtypes 
We are demonstrating 1118 epigenetically modified novel lncRNAs and previously reported disease-
associated lncRNAs within each subtype. Our work additionally underscores the importance of 
epigenetic alterations in modulating lncRNAs transcriptional activities. Although previous studies have 
demonstrated cross-talk between DNA methylation and transcriptional activities of lncRNAs, their role 
in the aetiology of BCP-ALL subtypes has not been investigated. DNA methylation analyses of lncRNAs 
revealed that DNA methylation might underlie the differential expression of BCP-ALL subtype-specific 
lncRNAs. 
4.11.1  Epigenetically altered lncRNAs within DUX4 subtype 
In the DUX4 subtype, we identified lincRNA PVT1, LINC00312 and TCL6 as differentially hypo-
methylated in the promoter region. Interestedly, lincRNA PVT1 is differentially hypo-methylated, with 
an up-regulated expression pattern in DUX4 samples. The lincRNA PVT1 is a well-defined lncRNA for 
its oncogenic properties (Colombo, Farina, Macino, & Paci, 2015) with multiple roles in cell growth, and 
differentiation in chronic and T-cell leukemia and many other solid tumors. However, there are no studies 
in the context of BCP-ALL subtypes. 
Other interesting examples are lncRNA LINC00312, and TCL6 were extensively studied on expression 
levels, but they are not studied at the epigenetic level. We are reporting its expression and DNA 
methylation profile in BCP-ALL subtypes. Both TCL6 and LINC00312 are lowly expressed in DUX4 
samples. Intriguingly, TCL6 is differentially up-regulated in ID compared to REL condition in the DUX4 
subtype. The lncRNA TCL6 is on-lncRNA reported in CLL due to its leukemogenic properties. However, 
it is not much documented in BCP-ALL. The TCL6, on-lncRNA is hyper-methylated and negatively 
correlating its expression pattern in the DUX4 subtypes. 
In addition to leukemia related lncRNAs, we also identified certain lncRNAs with prognostic value in 
other cancers. For instance, lncRNA LINC00472 is a tumor suppressor lncRNA in breast cancer. We 




transcriptome level. Besides known ones, we have identified 15 novel lncRNAs epigenetically up and 
down-regulating its expression profile in the DUX4 subtype. 
4.11.2  Epigenetically altered lncRNAs within Ph-like subtype 
In Ph-like subtype, lncRNAs such as SOX2-OT, MIR7-3HG and PVT1 are DM methylated at the 
promoter region. In Ph-like subtype, we identified PVT1 as hyper-methylated with a corresponding lower 
expression level in Ph-like samples. The lncRNA SOX2-OT is promoter hyper-methylated in the Ph-like 
subtype. Shahryari A et al. hints the genomic association of SOX2 and SOX2-OT resembles that of ANRIL 
and CDKN2B. Similarly, the lncRNA ANRIL resides in the intronic region of the protein-coding gene 
CDKN2B, in the antisense/opposite strand (Shahryari, Jazi, Samaei, & Mowla, 2015).  However, there 
are no direct reports of DNA methylation activity of SOX2-OT. 
 In addition to that, we have observed seven novel lncRNAs potentially epigenetically regulating their 
gene expression, out of these four were differentially hyper-methylated lncRNAs with down-regulated 
expression profile and three were differentially hypo-methylated lncRNAs with up-regulated expression 
profile within Ph-like samples. 
4.11.3  Epigenetically altered lncRNAs within NH-HeH subtype 
In NH-HeH subtype, we identified lncRNAs including, LINC00312, DANCR and IGF2-AS, as promoter 
differentially hypo-methylated and with a corresponding low expression level. In addition to the reported 
lncRNAs, we identified novel lncRNAs within our subtype which significantly facilitates its expression 
level. This observation was true for all three subtypes. These findings suggest that epigenetic silencing 
of lncRNA genes may be a mechanism that contributes to the dysregulation of expression of lncRNAs in 
BCP-ALL subtypes. 
Moreover, we identified 53 novel intronic and intergenic DM lncRNAs with super enhancer insulator 
chromatin markers from our subtypes, which provided a new context for further characterization. The 
probes for many lncRNA genes were not available in the DNA methylation microarray platform, some 
lncRNAs that are epigenetically regulated may not be identified in our analysis. Taken together, these 
results provide a valuable resource that will allow us to investigate epigenetically dysregulated lncRNAs 





My doctoral studies covered a number of aspects pertaining to the broad field of lncRNAs defining 
subtypes of BCP-ALL. The main conclusions of this studies presented in this thesis are: 
• We present a catalog of validated subtype-specific novel lncRNAs through our integrative 
analysis demonstrating the ability of lncRNAs to classify BCP-ALL subtypes 
• Subtype-specific lncRNAs and subtype-specific protein-coding genes are globally predicted to 
activate or inhibit the same pathways, which are involved in cell proliferation, apoptosis, 
differentiation in leukemia 
• Relapse-specific lncRNAs markers in ALL subtypes and these lncRNAs are associated with both 
keys signaling and metabolic pathways 
• Identified novel and known differentially methylated subtype-specific lncRNAs. 
• Epigenetically facilitated dysregulated subtype-specific lncRNAs from these subtypes. 
Together, these data extend the spectrum of known involvement of lncRNAs in BCP-ALL subtypes and 
represents BCP-ALL subtype-specific lncRNAs involved in key signaling and metabolic pathways. 
Additionally, we highlight key lncRNAs deregulated through epigenetic mechanisms. These findings 
may open promising avenues for the future studies to investigate key bio-markers and potential 
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Cancer associated lncRNAs from Lnc2Cancer databased lncRNAs identified within our DE BCP-ALL subtypes 
specific lncRNAs 
lncRNAs logFC Subtype 
WT1-AS 4.4467075041 DUX4 
IGF2-AS 4.9492924115 DUX4 
LINC00617 1.6149985664 DUX4 
RP11-528G1.2 1.5962063225 DUX4 
RGMB-AS1 5.9567554334 DUX4 
PVT1 1.1472967711 DUX4 
GAS5 0.7491196605 DUX4 
NAMA 2.5975131564 DUX4 
RP11-385J1.2 1.2329503925 DUX4 
EGOT -1.0943326581 DUX4 
CCDC26 -3.2170024233 DUX4 
MIR155HG -2.6518949391 DUX4 
ERICH1-AS1 -2.7489007994 DUX4 
SBF2-AS1 -1.3594259494 DUX4 
RP11-473M20.11 -0.8438258236 DUX4 
RP4-583P15.10 -1.5308828468 DUX4 
EGOT 1.274358117 Ph-like 
CCDC26 2.6225278418 Ph-like 
GAS6-AS1 1.9037862297 Ph-like 
SOCS2-AS1 1.0747748025 Ph-like 
ZEB1-AS1 1.5226204666 Ph-like 
ERICH1-AS1 2.213397887 Ph-like 
RP11-473M20.11 1.1719914008 Ph-like 




RGMB-AS1 -3.4663322292 Ph-like 
CRNDE -0.9892797054 Ph-like 
MYCNOS 1.7545902012 near-haploid 
ERICH1-AS1 3.06193078 near-haploid 
FTX 0.793491499 near-haploid 
LINC00961 2.3894010913 near-haploid 
WT1-AS -3.1921542827 near-haploid 
GAS6-AS1 -1.7290376602 near-haploid 
RP11-528G1.2 -1.2262908531 near-haploid 
GAS5 -0.90656684 near-haploid 
NAMA -2.5361169641 near-haploid 
 
Appendix B 
58 DUX4 specific lncRNAs correlated with the cis PC genes involved in different signaling pathways which are significantly 
enriched within DUX4 subtype 
Cis PC genes DUX4 specific lncRNAs Pearson correlation rate P-value 
ERG RP11-719K4.6 0.5768319431 1.41E-08 
ERG AC135048.13 0.5769253172 0.000000014 
ERG VIPR1-AS1 0.5724957843 1.92E-08 
FCGR1A CTD-2616J11.10 0.7385737284 2.39E-15 
FCGR1A AC069363.1 0.5663844552 2.92E-08 
FCGR1A CTD-2616J11.10 0.7385737284 2.39E-15 
FCGR1A AC069363.1 0.5663844552 2.92E-08 
FCGR1A CTD-2616J11.10 0.7385737284 2.39E-15 




IGF1R CTD-2528A14.1 0.7109735395 7.23E-14 
IGF1R CTC-523E23.4 0.6726852059 4.47E-12 
IGF1R CTB-25B13.9 0.6484099706 4.51E-11 
IGF1R RP11-1157N2-B.2 0.6173232018 6.54E-10 
IGF1R RP11-314O13.1 0.6143967848 8.28E-10 
IGF1R RP11-654A16.3 0.8986194406 2.34E-30 
IGF1R RP11-35O15.1 0.6743790376 3.77E-12 
IGF1R CTD-2134A5.3 0.5981854606 0.000000003 
IGF1R LINC00637 0.5503288421 8.51E-08 
IGF1R RP11-725G5.2 0.573910225 1.73E-08 
IGF1R RP11-186F10.2 0.6320289475 1.92E-10 
IGF1R RP11-87C12.5 0.704751345 1.48E-13 
IGF1R RP11-264E20.1 0.6218023229 4.53E-10 
IGF1R AF131215.3 0.6213166158 4.71E-10 
IGF1R RP11-166A12.1 0.6229334601 4.12E-10 
IGF1R CTD-2516F10.2 0.5737725158 1.75E-08 
IGF1R CTD-2187J20.1 0.5654915282 0.000000031 
IGF1R SMAD1-AS2 0.583731427 8.62E-09 
IGF1R RP11-713M15.1 0.5534522823 6.94E-08 
IGF1R SPTY2D1-AS1 0.6839701765 1.41E-12 
IGF1R RGMB-AS1 0.6594708095 1.61E-11 
IGF1R RP11-696N14.1 0.6367590983 1.27E-10 
IGF1R RP11-744N12.3 0.5740255383 1.72E-08 
IGF1R RP11-624M8.1 0.7066372789 1.19E-13 
IGF1R RP11-528G1.2 0.614170638 8.44E-10 
IGF1R AC114877.3 0.6621082443 1.26E-11 
IGF1R AC062029.1 0.6091826178 1.26E-09 




IGF1R RP11-465M18.1 0.6761671632 3.15E-12 
IGF1R RP11-63K6.7 0.5629188709 0.000000037 
IGF1R RP11-298A8.2 0.5590243606 0.000000048 
IGF1R LINC00954 0.6288612965 2.51E-10 
IGF1R RP11-563N6.6 0.6119674043 0.000000001 
IGF1R PCAT6 0.6841884724 1.38E-12 
IGF1R RP11-735G4.1 0.6342321907 1.58E-10 
IGF1R RP5-1077I2.3 0.5660757169 2.98E-08 
IGF1R LINC00694 0.568809002 2.47E-08 
IGF1R AC015977.6 0.624252876 3.7E-10 
IGF1R RP1-293L8.2 0.6415439113 8.36E-11 
IGF1R RP3-395M20.2 0.5851375181 7.78E-09 
IGF1R RP11-15H20.6 0.6028228348 2.06E-09 
IGF1R SRRM2-AS1 0.6099631582 1.18E-09 
IGF1R LINC01006 0.5932008351 4.29E-09 
IGF1R IGF2-AS 0.6394800895 1E-10 
IGF1R CTD-2528A14.1 0.7109735395 7.23E-14 
IGF1R CTC-523E23.4 0.6726852059 4.47E-12 
IGF1R CTB-25B13.9 0.6484099706 4.51E-11 
IGF1R RP11-1157N2-B.2 0.6173232018 6.54E-10 
IGF1R RP11-314O13.1 0.6143967848 8.28E-10 
IGF1R RP11-654A16.3 0.8986194406 2.34E-30 
IGF1R RP11-35O15.1 0.6743790376 3.77E-12 
IGF1R CTD-2134A5.3 0.5981854606 0.000000003 
IGF1R LINC00637 0.5503288421 8.51E-08 
IGF1R RP11-725G5.2 0.573910225 1.73E-08 
IGF1R RP11-186F10.2 0.6320289475 1.92E-10 




IGF1R RP11-264E20.1 0.6218023229 4.53E-10 
IGF1R AF131215.3 0.6213166158 4.71E-10 
IGF1R RP11-166A12.1 0.6229334601 4.12E-10 
IGF1R CTD-2516F10.2 0.5737725158 1.75E-08 
IGF1R CTD-2187J20.1 0.5654915282 0.000000031 
IGF1R SMAD1-AS2 0.583731427 8.62E-09 
IGF1R RP11-713M15.1 0.5534522823 6.94E-08 
IGF1R SPTY2D1-AS1 0.6839701765 1.41E-12 
IGF1R RGMB-AS1 0.6594708095 1.61E-11 
IGF1R RP11-696N14.1 0.6367590983 1.27E-10 
IGF1R RP11-744N12.3 0.5740255383 1.72E-08 
IGF1R RP11-624M8.1 0.7066372789 1.19E-13 
IGF1R RP11-528G1.2 0.614170638 8.44E-10 
IGF1R AC114877.3 0.6621082443 1.26E-11 
IGF1R AC062029.1 0.6091826178 1.26E-09 
IGF1R RP11-523O18.5 0.6478935766 4.73E-11 
IGF1R RP11-465M18.1 0.6761671632 3.15E-12 
IGF1R RP11-63K6.7 0.5629188709 0.000000037 
IGF1R RP11-298A8.2 0.5590243606 0.000000048 
IGF1R LINC00954 0.6288612965 2.51E-10 
IGF1R RP11-563N6.6 0.6119674043 0.000000001 
IGF1R PCAT6 0.6841884724 1.38E-12 
IGF1R RP11-735G4.1 0.6342321907 1.58E-10 
IGF1R RP5-1077I2.3 0.5660757169 2.98E-08 
IGF1R LINC00694 0.568809002 2.47E-08 
IGF1R AC015977.6 0.624252876 3.7E-10 
IGF1R RP1-293L8.2 0.6415439113 8.36E-11 




IGF1R RP11-15H20.6 0.6028228348 2.06E-09 
IGF1R SRRM2-AS1 0.6099631582 1.18E-09 
IGF1R LINC01006 0.5932008351 4.29E-09 
IGF1R IGF2-AS 0.6394800895 1E-10 
IGF1R CTD-2528A14.1 0.7109735395 7.23E-14 
IGF1R CTC-523E23.4 0.6726852059 4.47E-12 
IGF1R CTB-25B13.9 0.6484099706 4.51E-11 
IGF1R RP11-1157N2-B.2 0.6173232018 6.54E-10 
IGF1R RP11-314O13.1 0.6143967848 8.28E-10 
IGF1R RP11-654A16.3 0.8986194406 2.34E-30 
IGF1R RP11-35O15.1 0.6743790376 3.77E-12 
IGF1R CTD-2134A5.3 0.5981854606 0.000000003 
IGF1R LINC00637 0.5503288421 8.51E-08 
IGF1R RP11-725G5.2 0.573910225 1.73E-08 
IGF1R RP11-186F10.2 0.6320289475 1.92E-10 
IGF1R RP11-87C12.5 0.704751345 1.48E-13 
IGF1R RP11-264E20.1 0.6218023229 4.53E-10 
IGF1R AF131215.3 0.6213166158 4.71E-10 
IGF1R RP11-166A12.1 0.6229334601 4.12E-10 
IGF1R CTD-2516F10.2 0.5737725158 1.75E-08 
IGF1R CTD-2187J20.1 0.5654915282 0.000000031 
IGF1R SMAD1-AS2 0.583731427 8.62E-09 
IGF1R RP11-713M15.1 0.5534522823 6.94E-08 
IGF1R SPTY2D1-AS1 0.6839701765 1.41E-12 
IGF1R RGMB-AS1 0.6594708095 1.61E-11 
IGF1R RP11-696N14.1 0.6367590983 1.27E-10 
IGF1R RP11-744N12.3 0.5740255383 1.72E-08 




IGF1R RP11-528G1.2 0.614170638 8.44E-10 
IGF1R AC114877.3 0.6621082443 1.26E-11 
IGF1R AC062029.1 0.6091826178 1.26E-09 
IGF1R RP11-523O18.5 0.6478935766 4.73E-11 
IGF1R RP11-465M18.1 0.6761671632 3.15E-12 
IGF1R RP11-63K6.7 0.5629188709 0.000000037 
IGF1R RP11-298A8.2 0.5590243606 0.000000048 
IGF1R LINC00954 0.6288612965 2.51E-10 
IGF1R RP11-563N6.6 0.6119674043 0.000000001 
IGF1R PCAT6 0.6841884724 1.38E-12 
IGF1R RP11-735G4.1 0.6342321907 1.58E-10 
IGF1R RP5-1077I2.3 0.5660757169 2.98E-08 
IGF1R LINC00694 0.568809002 2.47E-08 
IGF1R AC015977.6 0.624252876 3.7E-10 
IGF1R RP1-293L8.2 0.6415439113 8.36E-11 
IGF1R RP3-395M20.2 0.5851375181 7.78E-09 
IGF1R RP11-15H20.6 0.6028228348 2.06E-09 
IGF1R SRRM2-AS1 0.6099631582 1.18E-09 
IGF1R LINC01006 0.5932008351 4.29E-09 
IGF1R IGF2-AS 0.6394800895 1E-10 
IGF1R CTD-2528A14.1 0.7109735395 7.23E-14 
IGF1R CTC-523E23.4 0.6726852059 4.47E-12 
IGF1R CTB-25B13.9 0.6484099706 4.51E-11 
IGF1R RP11-1157N2-B.2 0.6173232018 6.54E-10 
IGF1R RP11-314O13.1 0.6143967848 8.28E-10 
IGF1R RP11-654A16.3 0.8986194406 2.34E-30 
IGF1R RP11-35O15.1 0.6743790376 3.77E-12 




IGF1R LINC00637 0.5503288421 8.51E-08 
IGF1R RP11-725G5.2 0.573910225 1.73E-08 
IGF1R RP11-186F10.2 0.6320289475 1.92E-10 
IGF1R RP11-87C12.5 0.704751345 1.48E-13 
IGF1R RP11-264E20.1 0.6218023229 4.53E-10 
IGF1R AF131215.3 0.6213166158 4.71E-10 
IGF1R RP11-166A12.1 0.6229334601 4.12E-10 
IGF1R CTD-2516F10.2 0.5737725158 1.75E-08 
IGF1R CTD-2187J20.1 0.5654915282 0.000000031 
IGF1R SMAD1-AS2 0.583731427 8.62E-09 
IGF1R RP11-713M15.1 0.5534522823 6.94E-08 
IGF1R SPTY2D1-AS1 0.6839701765 1.41E-12 
IGF1R RGMB-AS1 0.6594708095 1.61E-11 
IGF1R RP11-696N14.1 0.6367590983 1.27E-10 
IGF1R RP11-744N12.3 0.5740255383 1.72E-08 
IGF1R RP11-624M8.1 0.7066372789 1.19E-13 
IGF1R RP11-528G1.2 0.614170638 8.44E-10 
IGF1R AC114877.3 0.6621082443 1.26E-11 
IGF1R AC062029.1 0.6091826178 1.26E-09 
IGF1R RP11-523O18.5 0.6478935766 4.73E-11 
IGF1R RP11-465M18.1 0.6761671632 3.15E-12 
IGF1R RP11-63K6.7 0.5629188709 0.000000037 
IGF1R RP11-298A8.2 0.5590243606 0.000000048 
IGF1R LINC00954 0.6288612965 2.51E-10 
IGF1R RP11-563N6.6 0.6119674043 0.000000001 




IGF1R RP11-735G4.1 0.6342321907 1.58E-10 
IGF1R RP5-1077I2.3 0.5660757169 2.98E-08 
IGF1R LINC00694 0.568809002 2.47E-08 
IGF1R AC015977.6 0.624252876 3.7E-10 
IGF1R RP1-293L8.2 0.6415439113 8.36E-11 
IGF1R RP3-395M20.2 0.5851375181 7.78E-09 
IGF1R RP11-15H20.6 0.6028228348 2.06E-09 
IGF1R SRRM2-AS1 0.6099631582 1.18E-09 
IGF1R LINC01006 0.5932008351 4.29E-09 
IGF1R IGF2-AS 0.6394800895 1E-10 
THBS4 RP11-455F5.5 0.5834534532 8.79E-09 
THBS4 AC006369.2 0.581104785 1.04E-08 
THBS4 RP11-206L10.3 0.6205508833 5.02E-10 
THBS4 AC009495.2 0.5729739692 1.85E-08 
THBS4 LINC01001 0.5885699321 6.05E-09 
THBS4 RP11-455F5.5 0.5834534532 8.79E-09 
THBS4 AC006369.2 0.581104785 1.04E-08 
THBS4 RP11-206L10.3 0.6205508833 5.02E-10 
THBS4 AC009495.2 0.5729739692 1.85E-08 
THBS4 LINC01001 0.5885699321 6.05E-09 
IFNG LA16c-380H5.2 0.6021783111 2.17E-09 
IFNG RP11-229P13.19 0.6873513366 9.92E-13 
IFNG AC006369.2 0.6132095599 9.11E-10 
IFNG RP11-206L10.3 0.5639277141 3.45E-08 
IFNG AC069363.1 0.5755674534 1.54E-08 




TPO CTD-2134A5.4 0.5924493 4.54E-09 
 
Appendix C 
24 Cis lncRNAs correlated with genes activated in signaling pathways in Ph-like subytpe 
Cis PC genes Ph-like specific lncRNAs Pearson correlation rate P-value 
ERG AC009970.1 0.6526738535 3.05E-011 
AGAP1 AC091814.3 0.5751982452 1.58E-008 
AGAP1 AGAP1-IT1 0.8032790178 1.09E-019 
AKT3 AKT3-IT1 0.6973830726 3.37E-013 
AGAP1 CRYM-AS1 0.7090921007 9.00E-014 
ERG FLNB-AS1 0.5648719539 3.24E-008 
AGAP1 IGF2-AS 0.5689062092 2.46E-008 
IFNG MIAT 0.5516374441 7.81E-008 
MLLT4 MLLT4-AS1 0.7485779553 6.23E-016 
AGAP1 RGMB-AS1 0.6187846799 5.80E-010 
IFNG RP11-1094M14.5 0.606262208 1.58E-009 
AGAP1 RP11-125B21.2 0.6099589362 1.18E-009 
ERG RP11-228B15.4 0.6340048541 1.62E-010 
ERG RP11-229P13.20 0.5607579369 4.28E-008 
AGAP1 RP11-332H18.4 0.5736201641 1.77E-008 
AGAP1 RP11-366M4.3 0.7741984559 1.47E-017 
AKT3 RP11-382A20.2 0.6097118707 1.20E-009 




AGAP1 RP11-481J2.2 0.5984889177 2.88E-009 
AGAP1 RP11-735G4.1 0.6853865908 1.22E-012 
AGAP1 RP11-744N12.3 0.5923224789 4.58E-009 
AGAP1 RP11-80H8.4 0.6215682327 4.62E-010 
ERG SOCS2-AS1 0.5923422688 4.58E-009 
AGAP1 ZEB2-AS1 0.55993078 4.52E-008 
Appendix D 
61 relapse-specific lncRNAs overlapped with prognostic markers (S-phase lncRNAs) from various cancers 
Hypergeometric test is done on the overlap between relapse-specific lncRNAs (864, without duplicated lncRNAs) on 634 S-phase prognostic 
lncRNAs from Pan-cancer paper, we got a P-value of 0.00026 on the overlap 
Geneid Log Fold change Subtype freq CANCERS 
ENSG00000271966 1.8985864055 Ph-like 2 KICH 
ENSG00000271966 1.8985864055 Ph-like 2 HNSC 
ENSG00000271797 1.8237031774 DUX4 1 LIHC 
ENSG00000214145 1.7741480353 NH-HeH 1 LIHC 
ENSG00000249635 1.5171090944 DUX4 1 KIRC 
ENSG00000225806 1.2744862632 DUX4 2 KIRC 
ENSG00000225806 1.2744862632 DUX4 1 LIHC 
ENSG00000267745 1.2531138011 DUX4 1 KIRC 
ENSG00000229989 1.208303717 DUX4 1 KIRC 
ENSG00000258210 1.178750383 DUX4 2 COAD 
ENSG00000224950 1.1622599607 DUX4 1 HNSC 
ENSG00000272377 1.1518481691 NH-HeH 1 STAD 
ENSG00000251141 1.0820345446 NH-HeH 1 KIRC 
ENSG00000235477 1.0368402864 DUX4 1 KIRC 
ENSG00000272377 1.0007919201 DUX4 1 STAD 




ENSG00000259005 0.9754401642 Ph-like 2 HNSC 
ENSG00000259005 0.9754401642 Ph-like 1 THCA 
ENSG00000245904 0.9697603784 NH-HeH 1 KIRC 
ENSG00000245904 0.9697603784 NH-HeH 1 HNSC 
ENSG00000253854 0.9683243951 NH-HeH 1 HNSC 
ENSG00000258458 0.9658526226 NH-HeH 2 KICH 
ENSG00000132832 0.9542306016 NH-HeH 2 KIRC 
ENSG00000132832 0.9542306016 NH-HeH 1 KIRC 
ENSG00000269275 0.950853756 Ph-like 1 KIRP 
ENSG00000273007 0.9293166535 DUX4 1 KICH 
ENSG00000229956 0.9230710207 DUX4 3 BLCA 
ENSG00000257496 0.9071366649 DUX4 1 KIRC 
ENSG00000273321 0.8869802261 Ph-like 1 KIRC 
ENSG00000232995 0.8461955111 DUX4 2 KICH 
ENSG00000254343 0.8409647741 DUX4 1 KIRC 
ENSG00000261971 0.8122099133 DUX4 1 KIRC 
ENSG00000261971 0.8122099133 DUX4 1 HNSC 
ENSG00000255142 0.8026421154 NH-HeH 1 KIRC 
ENSG00000271270 0.7972751156 DUX4 2 KICH 
ENSG00000271270 0.7972751156 DUX4 1 LIHC 
ENSG00000262903 0.790551093 NH-HeH 2 HNSC 
ENSG00000262903 0.790551093 NH-HeH 1 KIRC 
ENSG00000203327 0.7777332889 DUX4 2 KIRC 
ENSG00000203327 0.7777332889 DUX4 1 KIRC 
ENSG00000249684 0.7751868547 DUX4 1 KIRC 
ENSG00000203327 0.7723922873 NH-HeH 2 KIRC 
ENSG00000203327 0.7723922873 NH-HeH 1 KIRC 




ENSG00000231154 0.7402699106 NH-HeH 1 HNSC 
ENSG00000225177 0.7323191686 DUX4 2 COAD 
ENSG00000225177 0.7323191686 DUX4 2 KIRC 
ENSG00000245904 0.724870551 DUX4 1 KIRC 
ENSG00000245904 0.724870551 DUX4 1 HNSC 
ENSG00000227953 0.7215896414 DUX4 3 COAD 
ENSG00000227953 0.7215896414 DUX4 2 COAD 
ENSG00000231160 0.719501534 DUX4 1 HNSC 
ENSG00000251141 0.7055409481 DUX4 1 KIRC 
ENSG00000272142 0.7051632182 DUX4 2 BLCA 
ENSG00000272142 0.7051632182 DUX4 2 BLCA 
ENSG00000237489 0.7044213697 DUX4 1 HNSC 
ENSG00000251432 0.6928448368 DUX4 2 KICH 
ENSG00000242798 0.6656524129 DUX4 2 KIRC 
ENSG00000242798 0.6656524129 DUX4 1 KIRC 
ENSG00000251661 0.6521627605 DUX4 1 BRCA 
ENSG00000179406 0.6341635179 DUX4 1 KIRC 
ENSG00000179406 0.6341635179 DUX4 1 KIRC 
ENSG00000228544 0.6248451995 DUX4 1 KIRC 
ENSG00000232931 0.6190056715 DUX4 2 HNSC 
ENSG00000232931 0.6190056715 DUX4 2 HNSC 
ENSG00000240291 0.6188511007 DUX4 2 HNSC 
ENSG00000240291 0.6188511007 DUX4 1 KIRC 
ENSG00000231770 0.5830600454 DUX4 1 BRCA 
ENSG00000260219 -0.6415049402 DUX4 1 HNSC 
ENSG00000237471 -0.696257352 DUX4 1 KIRC 
ENSG00000203999 -0.7656032616 DUX4 3 BRCA 




ENSG00000237476 -0.7724465539 DUX4 2 BRCA 
ENSG00000237476 -0.7724465539 DUX4 1 LUSC 
ENSG00000223486 -0.7978375931 DUX4 1 KIRC 
ENSG00000269959 -0.8649871927 DUX4 2 HNSC 
ENSG00000269959 -0.8649871927 DUX4 2 KICH 
ENSG00000261189 -0.972774636 DUX4 2 BLCA 
ENSG00000262152 -1.0599678801 DUX4 2 COAD 
ENSG00000262152 -1.0599678801 DUX4 2 COAD 
ENSG00000272502 -1.0857976669 NH-HeH 3 BRCA 
ENSG00000272502 -1.0857976669 NH-HeH 2 KIRP 
ENSG00000258701 -1.1876038012 DUX4 1 BLCA 
ENSG00000248323 -1.1894163242 DUX4 3 KICH 
ENSG00000248323 -1.1894163242 DUX4 3 KIRC 
ENSG00000234432 -1.2407728884 NH-HeH 1 HNSC 
ENSG00000259498 -1.3129758934 NH-HeH 1 BLCA 
ENSG00000261584 -1.5542111472 DUX4 1 KIRC 
ENSG00000261584 -1.5542111472 DUX4 1 HNSC 
ENSG00000229619 -1.9591715435 NH-HeH 1 THCA 
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